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Abstract 
Fungal infections have become a major problem in the hospital sector in the past decades due to the 
increased number of immune compromised patients susceptible to mycosis. Most human infections are 
believed to be associated with biofilm forming cells that are up to 1000-fold more tolerant to antimicrobial 
agents compared to their planktonic counterparts. Antifungal treatment of biofilms will therefore often 
result in treatment failure. Consequently, there is a basic requirement to understand the underlying 
tolerance mechanisms and to development of novel anti-biofilm treatment strategies. 
The focus of this thesis has been to explore the tolerance mechanisms of yeast biofilms to systemic 
antifungal agents and to identify the molecular target of a novel peptidomimetic with anti-biofilm activity. 
The genetic tractable S. cerevisiae was used as biofilm model system for the pathogenic Candida species in 
an attempt to take advantage of the molecular tools available for S. cerevisiae.  
Mature biofilms containing mainly growth arrested cells were shown to be tolerant to three out of four 
tested antifungals, while all drugs had inhibitory activity against proliferating biofilm cells, demonstrating 
that drug treatment efficacy of biofilm cells is highly dependent on cellular growth phase. Similar results 
were obtained for planktonic cells, showing that ceased proliferation is a shared tolerance mechanism 
between biofilm and planktonic cells.  
It was found that the membrane pore-forming agent amphotericin B was the only tested drug with activity 
against both growth arrested biofilm and planktonic cells but was found to only kill ~95 % of the cells. By 
using a collection of barcode tagged deletion mutants, we were identified that defects in protein synthesis, 
intracellular transport, cell cycle and lipid metabolism resulted in increased amphotericin B tolerance in 
both biofilm and planktonic cells. We furthermore observed that the tolerance level could be enhanced by 
nutrient starvation and inhibition of the TOR pathway. 
In conclusion, antifungal tolerance is the combined effect of the physiological state of the cell and the 
mechanism of action of the drug, and this is independent of mode of growth. Based on these results, it can 
be suggested that future drug treatment strategies should focus on targeting growth arrested cells, rather 
than distinguishing between modes of growth. 
At last, we analyzed the antifungal activity of the novel peptidomimetic LTX-109. We showed that this 
molecule rapidly killed yeast cells and that cell death was associated with release of protons, potassium and 
amino acids to the extracellular environment. Screening a yeast deletion collection for LTX-109 resistance 
indicated that complex sphingolipids were involved in fungicidal activity of LTX-109. The sphingolipids may 
therefore represent a unique antifungal target with therapeutic potential for future drug development. 
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Dansk resumé 
Svampeinfektioner er blevet et stort problem i hospitalssektoren i løbet af de sidste årtier fordi andelen af 
patienter med nedsat immunsystem, der er følsomme overfor mycosis, er steget. Det skønnes at de fleste 
infektioner i mennesker er associerede med biofilmdannende celler, der er op til tusind gange mere 
tolerante overfor antimikrobielle stoffer sammenlignet med planktoniske celler. Der er derfor et behov for 
at forstå de underliggende tolerancemekanismer, samt udvikle nye anti-biofilm behandlingsstrategier. 
Der har i denne afhandling været lagt fokus på at undersøge biofilmcellernes tolerancemekanismer overfor 
systemiske antifungaler, samt at identificere det molekylære target for et nyt peptidomimetic med anti-
biofilm aktivitet. S. cerevisiae blev brugt som biofilm modelsystem for de patogene Candida arter i et forsøg 
på at udnytte de mange molekylære værktøjer, der er til rådighed for S. cerevisiae. 
Modne biofilm, der hovedsageligt bestod af ikke voksende celler var tolerante overfor tre ud af de fire 
antifungaler som blev testet i dette studie, hvorimod alle stofferne havde inhibitorisk aktivitet overfor 
voksende biofilmceller. Disse resultater viste at aktiviteten af antifungalerne var afhængig af 
cellevækstfase. Lignende resultater blev observeret med planktoniske celler, hvilket viste at manglende 
vækst var en delt tolerancemekanisme mellem biofilm og planktoniske celler. 
Det blev fundet at det membranporedannende stof amphotericin B var det eneste testet stof, der dræbte 
både ikke-voksende biofilm og planktoniske celler. Amphotericin B var dog kun i stand til at dræbe ~95 % af 
cellerne. Der blev derfor foretaget et barcode sekventeringsscreen af en blandet samling af gendeleterde 
mutanter for at bestemme de molekylære mekanismer, der resulterede i amphotericin B overlevelse. Det 
blev fundet at fejl i proteinsyntese, intracellulær transport, cellecyklus og lipid metabolisme førte til øget 
amphotericin B tolerance i både biofilm of planktoniske celler. Derudover observerede vi at 
toleranceniveauet kunne øges ved næringsstofsult on inhibering af TOR pathway. 
Disse resultater viser at tolerance overfor antifungale stoffer er den samlede effekt af cellens fysiologiske 
tilstand og stoffernes virkemekanismer. Det kan på baggrund af disse data foreslås at fremtidige 
behandlingsstrategier skal fokusere på at ramme ikke-voksende celler i stedet for at skelne mellem biofilm 
og planktonisk vækst. 
I den sidste del af afhandlingen blev det fundet at det nye peptidomimetic LTX-109 hurtigt dræbte 
gærceller, hvilket resulterede i udstrømning af protoner, kalium og aminosyrer. En samling af 
gendeleterede mutanter blev screenet for at identificere LTX-109 resistente mutanter, hvilket viste at 
komplekse sfingolipider var involverede i den fungicide aktivitet af LTX-109. Sfingolipiderne er unikke 
antifungale targets med stort potentiale for udvikling af fremtidige behandlingsstrategier. 
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1. Introduction 
Microbial biofilms have been thoroughly studied since Bill Costerton and colleagues linked biofilm 
formation to human disease in the early 1980s and it was observed that biofilm cells can survive high 
concentrations of antimicrobial agents. Despite decades of research, the molecular mechanisms underlying 
drug tolerance of biofilm cells are not fully understood. Several mechanisms have been proposed to be 
involved, but none of them can solely account for treatment failure. This research subject is therefore 
highly relevant and extensively investigated. As of April 2014, PubMed listed >2400 publications in which 
the words “biofilm” AND “resistance” appear in “title/abstract” and the number of publications are 
increasing every year (Figure 1).  
 
 
Figure 1. Number of publications on biofilm resistance. The number of publications containing the words "biofilm" and 
"resistance" in the title and/or abstract increase every year. Data from (pubmed.com). 
The major subject of this thesis was to investigate the multidrug tolerance mechanisms of microbial biofilm 
cells. The research was performed in yeast that has become a major nosocomial problem during the past 
decades. Although biofilms caused by Candida species were among the first to be observed on invasive 
medical devices in the clinic [1], knowledge about yeast biofilms is limited compared to bacterial biofilms, 
possible due to the lack of genetic and molecular tools available for pathogenic fungi [2,3]. We therefore 
aimed at developing a model system using Saccharomyces cerevisiae to study yeast biofilms and take 
advantage of the molecular tools available for this fungus.  
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1.1 The term "biofilm" 
Early publications of the word "biofilm" originate from marine microbiology that used the term to describe 
microbes trapped in wastewater filters in aquatic environments [4,5].  "Biofilm" was used in relation to 
human infection for the first time in 1984 [1], but Anthony van Leeuwenhoek has retrospectively been 
acknowledged as the first scientist to publish observations of biofilms with his microscopic investigations of 
aggregating cells on tooth surfaces (published in 1684) [6,7]. Research in the 1970s and 80s pioneered by 
Bill Costerton led to the classic definition of a biofilm: "a structured community of [...] cells enclosed in a 
self-produced polymeric matrix and adherent to an inert or living surface" [8]. Development and 
implementation of advanced microscopic techniques and transcriptomic analysis in biofilm research 
expanded the definition of biofilms to include that phenotypic profiles must be distinct from their 
planktonic counterparts [9]. Massive attention has been on antimicrobial recalcitrance of biofilm cells in the 
past decades. Although originally not a defining criterion for biofilms, the resistance to high concentrations 
of antimicrobial agents is today considered as one of the major hallmarks of microbial biofilms [10-12].  
Recent in vivo research have led to an updated definition of biofilm that matches the lifestyle of infectious 
microbes observed in the clinic with aggregation and tolerance to antimicrobial agents as the two major 
biofilm characteristics [13]. With this definition it is no longer necessary to be surface attached or be 
encapsulated in a self-produced matrix as was dictated by the early biofilm dogma. Today, "biofilm" is used 
to describe several in vitro modes of growth including colonies on solid agar [14,15], free-floating 
aggregates [16] and attachment to an abiotic surface in liquid environments [17]. The latter in vitro model 
system has been used in this thesis for biofilm cultivation. 
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2. Candida infections 
Candida is a genus of yeasts belonging to the kingdom fungi. Candida species can be isolated from soil and 
aquatic environments, but are also commonly found as a member of commensal human microbiota 
including the oral cavity, skin, gastrointestinal and genitourinary tract [18]. Candida species are 
opportunistic pathogens that can cause infections ranging from superficial to life-threatening systemic 
disease (Figure 2). Young and healthy individuals rarely become infected with fungi, while infants and the 
elderly are more at risk [19]. Candida are frequently isolated from immune compromised patients with 
HIV/AIDS, cancer, invasive medical devices or severe burn wounds [20]. Improvements in modern medicine 
and changes in medical practice have led to an extensive use of invasive medical devices, cancer 
chemotherapy and broad spectrum antimicrobials, which simultaneously have increased the population at 
risk of fungal infections [20,21].  
 
 
Figure 2. Routes of entry and distribution of fungal infections in humans. Pathogenic fungi can enter the human host at diverse 
sites causing infections ranging from superficial to deep seated mycosis. Figure adapted from Moore et al. (2011) [22]. 
 
Candida is the most frequently isolated fungal species from patients with fungemia [19] and it is now 
accepted as a major human pathogen in the nosocomial sector. Candida is the fourth leading cause of 
hospital acquired blood stream infections and catheter-related infections in USA with mortality rates at 
40% [23,24]. Furthermore, Candida causes oral thrush in the majority of AIDS patients [25].  
Candida infections 
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C. albicans is the most prevalent among fungal blood isolates accounting for approximately 50% of the 
incidences [26,27], but an increase in non-Candida albicans species have been reported in the past 
decades. This might be a result of the extensive use of fluconazole that has selected for intrinsic resistant 
Candida species such as C. glabrata and C. krusei [20,28,29]. 
 
2.1 Clinical significance of yeast biofilms 
Dental plaques on tooth surfaces was one of the first examples of microbial biofilms to be recognized by 
the nosocomial sector [21], and it is presently estimated that most human infections are associated with 
biofilm formation [30-32]. Yeast infections are often associated with invasive medical devices that serve as 
a compatible surface for cell adhesion and biofilm formation. The increase in Candida infections has almost 
paralleled the increased use of medical implants in immune compromised patients [33,34]. Fungal biofilms 
can form on almost any medical device including catheters, prostheses, implants and cardiovascular devices 
[21,33]. The invasive device can be contaminated by the microflora of the patient or externally by i.e. hands 
of nursing staff [2,21]. The cells in a biofilm can cause chronic infection at the attachment site or they can 
detach from the biofilm and cause infection at other sites of the human body [35].  
 
2.2 Biofilm development 
Yeast biofilms develop in four stages that  occur overlapping rather than sequential [36] (Figure 3). The 
initial step is attachment of single cells to a surface through non-specific interactions followed by the 
expression of specific adhesins for stronger attachment [20]. Yeast biofilm adhesins are cell surface 
glycoproteins rich in the amino acids serine and threonine [36]. Next, the yeast cells proliferate and 
colonize the surface in aggregates, while secreting an extracellular matrix. The matrix has been suggested 
to support surface adhesion, facilitate stress tolerance and create reservoirs for nutrients and waste 
products [37,38]. The extracellular matrix consists mainly of carbohydrates and proteins that accumulate in 
the maturation process and lead to a well-organized multicellular structure with extensive spatial 
heterogeneity. The mature biofilm structure depend on environmental conditions, while the amount of 
extracellular matrix material and cell morphology differentiate between the Candida species [20]. In the 
last step, cells disperse from the biofilm with the ability to infect various sites in the host as planktonic cells 
or form a new biofilm at another location [36].  
Candida infections 
 5 
 
Figure 3. Candida biofilm development. In the first step of biofilm formation, planktonic yeast cells attach to a surface using 
adhesins. Next, the yeast cells proliferate and colonize the surface in aggregates forming a multicellular community. Some Candida 
species form hyphae while others only consist of yeast morphology. The biomass increases in the maturation process and the cells 
excrete an extracellular matrix that encapsulates the biofilm cells. The yeast cells can disperse from the biofilm and form a new 
biofilm at another site or cause infection as planktonic cells. Figure modified from Finkel and Mitchell (2011) [36]. 
 
Microbial cells can coordinate gene expression by sensing the accumulation of self-produced quorum 
sensing (QS) molecules in the environment. QS signaling is known to be a key regulator of bacterial biofilm 
formation [39], but less is known about their role in yeast biofilms. Several QS molecules have been 
observed to accumulate in mature yeast biofilms [36]. Furthermore, addition of the autoinducer farnesol 
results in disruption of the biofilm structure, suggesting a role of this molecule in biofilm stability and 
formation [40,41]. 
 
2.3 Treatment of biofilm infections 
The link between fungal infections and biofilm formation originates from the detection of surface attached 
fungi on medical invasive devices after removal from the patient [42]. However, there is currently no 
diagnostic test available for clinicians to detect biofilm infections. Instead, several observations have been 
suggested to indicate biofilm associated infections: clinical symptoms of fungal infection, antifungal 
treatment failure or recurrent infections, the use of indwelling devices, and microscopic detection of 
multicellular aggregates [43].  
There are four major drug treatment options for biofilm-associated fungal infections: antifungal mono and 
combination therapy, prophylaxis and surgical removal of biofilm-infected implants.  
 
2.3.1 Antifungal monotherapy 
Fungal infections are treated with systemic antifungals from four major drug classes (Figure 4). 
 
Azoles 
The azoles are a group of antifungal agents that target the cytochrome P450 enzyme lanosterol-14α-
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demethylase. The demethylase is encoded by the gene ERG11 and is responsible for the conversion of 
lanosterol to ergosterol. Inhibition of this enzymatic step results in ergosterol depletion and accumulation 
of toxic ergosterol procurers and the cell consequently cease proliferation [29,44]. The activity of most 
azoles is considered fungistatic. Azoles can be divided into imidazoles (miconazole, ketoconazole, 
clotrimazole), which are used in topical treatment and triazoles (fluconazole, itraconazole, voriconazole, 
posaconazole) that are developed for systemic treatment. The triazoles are the most frequently used drugs 
for treatment of mild to moderate systemic mycosis because of their favorable pharmacokinetic and 
pharmacodynamic properties [44,45].   
 
Polyenes 
The polyenes (amphotericin B and nystatin) are produced by Streptomyces and have been used in the clinic 
since the 1950s. They target ergosterol in the fungal cell membrane where binding alone is sufficient for 
antifungal activity because it inhibit vital processes controlled by ergosterol [46]. Another mechanism of 
action is pore-forming aggregation of polyenes in the lipid bilayer that facilitate efflux of ions and larger 
electrolytes [44,47]. Amphotericin B is the dominating polyene in clinical practice and it has fungicidal 
properties that result in rapid cell lysis. Amphotericin B has a broad spectrum of activity and is the gold 
standard for treatment of life threatening systemic infections [47,48].  The high homology of the fungal 
ergosterol to the human cholesterol results in severe toxic side effects from amphotericin B use. However, 
several amphotericin B formulation have been developed to limit the toxic side effects [49]. 
 
Flucytosine 
The fluoropyrimidine 5-flucytosine is a pro-drug that is transported into the cell by cytosine permease. 
Conversion of the drug to fluorodine triphosphate can be incorporated into RNA in place of uridylic acid 
and result in inhibition of protein synthesis. Another mechanism of action is the processing of 5-flucytosine 
to 5-fluorodeoxyuridine monophosphate, which acts on thymidylate synthase to inhibit DNA synthesis 
[50,51]. The effect of flucytosine is growth inhibition of susceptible fungal cells [44]. Monotherapy with 
flucytosine is limited because of a high frequency of resistance development. Consequently, the use of 
flucytosine is often restricted to combination therapy with amphotericin B or triazoles [51]. 
 
Echinocandins 
The echinocandins (caspofungin, anidulafungin, micafungin) consist of a family of lipopeptides that inhibit 
the cell wall β-1,3-D-glucan synthase complex. The echinocandins target the catalytic subunit Fks that is 
encoded by the genes FKS1, FKS2 and FKS3 leading to disruption of cell wall structure and osmotic 
Candida infections 
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instability [44,52]. Treatment with echinocandins cause cell lysis and the drugs are fungicidal against 
Candida species and fungistatic against Aspergillus species [52,53]. The echinocandins have a narrow 
spectrum of activity and their use are often limited to invasive candidiasis [52]. 
 
 
 
 
Figure 4. Mechanism of action of antifungal agents. (A) The triazoles inhibit ergosterol biosynthesis by binding to cytochrome 
P450, which cause accumulation of toxic sterols. (B) The polynes bind to ergosterol in the cytoplasmic membrane and form pores 
that lead to efflux of intracellular ions and electrolytes. (C) Flucytosine inhibits DNA and protein synthesis. (D) The echinocandins 
target Fks1 of the cell wall β-1,3-D-glucan synthase complex and inhibit cell wall synthesis. Figure adapted from Cowen and 
Steinbach (2008) [54]. 
Candida infections 
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2.3.2 Antifungal combination therapy 
Combination therapy with two or more antifungal drugs can be used if they have synergistic effect. But it 
can also be used to decrease the concentration of amphotericin B to reduce the risk of toxic side effects, or 
to limit resistance development associated with flucytosine use [42,43]. One advantage of combination 
therapy can be to simultaneously target several biofilm subpopulations that each might express antifungal-
specific resistance mechanisms. 
 
2.3.3 Prophylaxis 
Biofilm formation on medical invasive devices can be inhibited by prophylactic treatment of the device. This 
can be done by sterilizing the device by flushing it for hours with an inhibitory agent, or the device can be 
coated with an agent that prevents binding to the device. Antifungal lock therapy is another solution where 
a high concentration of an antimicrobial agent is introduced to the lumen of the catheter and “locked” for 
extensive time without being in use [10,42,43]. The goal is to reduce the risk of colonizing the catheter with 
a pathogen, but development of antimicrobial resistance is a major concern [10].   
 
2.3.4 Removal of invasive device 
The most efficient treatment of a device-related biofilm infection is to replace or remove the implant. This 
procedure is not always desirable, because of patient inconvenience and often life-supporting function of 
the medical implants [10,42,43].   
Antifungal resistance 
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3. Antifungal resistance 
 
3.1. Inherited resistance 
Failure to eradicate a fungal infection by antifungal treatment can be attributed to microbial or clinical 
resistance mechanisms. Microbial resistance refers to the inactivity of an antifungal drug against an 
unsusceptible fungus and can be intrinsic or acquired [55,56]. The fungus is intrinsic resistant to an 
antifungal agent if it can resist the drug without prior exposure. Intrinsic resistance can be observed in C. 
glabrata and C. krusei to some azoles and in Cryptococcus neoformans to echinocandins [56,57].  
Acquired resistance is the development of resistance in a susceptible strain. Mutations in antifungal drug 
targets that result in decreased drug affinity are the most common resistance mechanism and can be 
applied to most antifungals. Mutations in ERG11 that encode the target of azoles prevent binding to the 
enzymatic site. Similarly, mutations in FKS1 inhibit the binding of echinocandins to the β-1,3-D-glucan 
synthase complex. Resistance to polyenes is often a result of mutations in the ergosterol biosynthetic 
pathway genes that result in the accumulation of ergosterol intermediates in the cell membrane [56]. C. 
albicans has two major efflux pump families that are encoded by the CDR and MDR genes and upregulation 
of these genes increase drug export out of the cell [56]. Only the azoles are substrate to Candida species 
efflux pumps, while no efflux pumps have been observed to transport the polyenes or echinocandins out of 
the cell [29,56,58]. Resistance to flucytosine is mediated by mutations in cytosine permease or cytosine 
deaminase that are responsible for uptake and conversion to the active compound, respectively [51,57]. 
Enzymes that interfere with antifungal activity have not been discovered in fungi [59] and intact fungi are 
unsusceptible to horizontal gene transfer without cell fusion [57]. Evolution of antimicrobial resistance in 
fungi is therefore a result of local mutations. Mutations that result in antifungal resistance are drug specific 
and observations of multidrug resistant strains in the clinic are extremely rare [29].  
Clinical resistance is the persistence of infection despite antifungal treatment and includes survival of 
susceptible strains [55]. Such treatment failure can be caused by wrong diagnosis, the underlying disease of 
the patient, pharmacokinetics or pharmacodynamics, and the physiological state of the cell such as those in 
biofilms [56,57,60].  
 
3.2 Tolerance of fungal biofilms to antifungal agents 
The ability of microbial biofilms to survive treatment with high doses of antimicrobial agents is attributed to 
tolerance mechanisms rather than inherited resistance [61,62]. In contrast to the classic definition of 
antimicrobial resistance, which can be acquired by mutations of chromosomal genes or uptake of external 
DNA, non-inherited resistance is caused by phenotypic variations of susceptible cells [63]. Such non-
inherited resistance also known as persistence will for consistency in this thesis be referred to as tolerance. 
Antifungal resistance 
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Antimicrobial drug tolerance has been given little attention compared to genetically altered resistance, 
although the importance of such non-inherited survival mechanisms is well documented and could develop 
into inherited resistance [61,63]. Candida biofilms have been suggested to possess several antifungal drug 
tolerance mechanisms that will be discussed below. 
 
Extracellular matrix 
One of the hallmarks of biofilm cells is the production of an extracellular matrix. One appealing suggestion 
is that it prevents the antimicrobial agents from reaching their targets either by physical blocking the 
penetration or by interactions between the antimicrobial drug and extracellular matrix components. Such 
shielding would depend on the physiochemical properties of the matrix and drug, and will not be applied 
for all drug classes because of the chemical diversity and molecule size of antimicrobial agents [64]. 
Research on Candida species biofilms with antifungal agents have shown that drug inactivity is not 
dependent on the amount of matrix produced by biofilm cells [65], and that the antifungal agents can 
penetrate the matrix layer in concentrations that kill exponential growing planktonic populations [66]. It 
has therefore been concluded that the matrix material does not play a significant role in antifungal 
tolerance of fungal biofilm cells [65,66]. The matrix layer may, however, have a much more significant role 
in surviving exposure to immune cells during infection [67].  
 
Efflux pumps 
Efflux pumps are common resistance mechanisms to the azole drug fluconazole in planktonic Candida 
populations. Since fluconazole has poor activity against Candida biofilms, this has led to the investigation of 
the involvement of major efflux pumps in biofilm associated drug tolerance. While upregulation of efflux 
pumps have been reported in the early and intermediate phases of biofilm development, but lost in the 
mature phase [68,69], others find them to be upregulated during all growth phases of biofilm development 
[70]. Despite this inconsistency, there is an agreement that efflux pump gene knockouts remain fluconazole 
tolerant [68,69,71] and efflux pumps can therefore not solely be responsible for the observed drug 
tolerance in biofilm cells. Furthermore, since the polyenes and echinocandins are not substrates to any 
known efflux pumps, they cannot account for the multidrug tolerance to these drugs [58].  
 
Decreased drug target levels 
Tolerance of biofilm cells might be achieved by decreased drug target levels. It has been observed that 
intermediate and mature phase biofilm cells have decreased membrane ergosterol levels [69], which result 
in fewer target molecules for the polyenes [72].  
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Slow growth 
Biofilms typically inhabit nutrient limited environments and the starvation conditions result in decreased 
growth rate and metabolism of the biofilm cells. Especially cells located in the inner layer of biofilms have 
poor nutrient access and consequently have reduced cellular metabolism [73]. The inhibitory effect of 
antimicrobial agents is anti-correlated to growth rate and is highly dependent on cell division [63,74-76]. 
Accordingly, most systemic antifungals have activity against proliferating biofilm cells [77], but are inactive 
against mature biofilms [78].  
 
Heterogeneity 
Biofilm populations have a high level of phenotypic heterogeneity that can be attributed to nutrient and 
oxygen gradients across the biofilm [73,79]. Sub-populations may use different tolerance mechanisms and 
therefore, none of the mechanisms described above can individually account for the multidrug tolerance 
observed in biofilm cells. It is possible that a combined effect of each tolerance mechanism contribute to 
the overall tolerance, hence, drug treatment can only eradicate the entire biofilm population if it targets all 
sub-populations.
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4. Stress tolerance 
 
4.1 Phenotypic heterogeneity 
Phenotypic variation between microbial cells in isogenic populations increases fitness in fluctuating 
environments. Heterogeneous populations are likely to contain cells that are more tolerant to acute stress 
exposure than homogeneous populations adapted to constant environments [80,81]. Several factors can 
contribute to phenotypic heterogeneity that results in diverse gene expression patterns among individual 
cells. Each cell cycle phase is associated with specific transcriptional activity and asynchronous cell cycle 
progression of individual cells will therefore result in gene expression variations [82]. The rate of cell cycle 
progression is correlated to cell age and replicative older cells with slow cell cycle progression will therefore 
have distinct gene expression compared to replicative younger cells [80,83] (Figure 5). Indeed, cell cycle 
phase, growth rate and cell age have all been linked to increased tolerance to environmental stress 
[80,82,83].  
 
 
Figure 5. Population heterogeneity. Individual cells in a population divide asynchronously and result in cells with age and cell cycle 
stage variations. Cell cycle progression and cell age can drive population heterogeneity because different gene expressions are 
associated with cell cycle stage, growth rate and age of the cell. Figure adapted from Sumner and Avery (2002) [82]. 
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Population heterogeneity can also be generated by stochastic variation in gene expression. Such 
stochasticity can be the result of protein or mRNA abundance diversity among individual cells that is caused 
by random synthesis and degradation rates. Gene expression can occur in pulsatile bursts, which give 
episodic protein synthesis in oppose to a constitutive gene expression. Translational bursting is a stochastic 
event that generates random variation in molecular processes during protein synthesis and cell division 
[81,84,85]. Stochasticity generates cell individuality independent on environmental cues and increases the 
likelihood of survival in fluctuating environments [81]. Phenotypic heterogeneity can also be a deterministic 
switch induced in response to stress exposure. 
 
4.2 Environmental stress tolerance 
The ability of microorganisms to survive fluctuating and stressful conditions depends on rapid changes in 
gene expression. Stress response in yeast is controlled by stress-activated protein kinase (SAPK) pathways 
that regulate transcription factors, kinases, cell cycle regulators and membrane proteins for adaptation of 
the internal milieu to the environmental conditions [86]. As a result, a common transcription response 
called the environmental stress response (ESR) is induced in yeast that entails inhibition of protein 
synthesis and activation of energy storage catabolism. Consequently, the cell enters a low metabolism 
quiescent state with increased stress tolerance [87,88]. However, genes induced by response to acute 
stress are not essential for surviving that stress, but rather prepare the cell for future stimuli. The initial 
stress triggers the ESR that serves a protective role for subsequent stimuli, and the second stress induce 
genes that are condition-specific and essential for survival [89,90]. Evolutionary selection for 
microorganisms in fluctuating stressful environments imposes a trade-off between fast growth and high 
stress tolerance [91]. While homogeneous, fast growing populations have high fitness in constant 
environments, phenotypic population heterogeneity ensures population survival in changing environments 
[80]. The strong anti-correlation between growth rate and stress survival can be observed in planktonic 
stationary state cells and mature biofilm cells that both contain heterogeneous populations with low 
cellular metabolism and high stress tolerance levels [92].   
 
4.3 Quiescence 
Yeast cells can exit the cell cycle and enter a growth arrested state called quiescence. This state can be 
induced by exposure to stress and has been well characterized for nutrient starved cells. The growth arrest 
is temporary and can be reversed by the addition of nutrients.  
It is the general assumption that once yeast cells pass a restriction point in the cell cycle G1 phase called 
START, they are committed to pass through all cell cycle phases until they reach the restriction point again 
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[93]. The cell can pass START in the presence of a good quality carbon source, but fail to do so in nutrient 
poor environments. Instead, the G1 cells enter the G0 phase, which is a quiescent growth arrested state [94] 
(Figure 6). This assumption was recently challenged with the observation that yeast cells can enter a 
quiescent state in all cell cycle phases [95]. Nonetheless, quiescent cells are most frequently observed in 
the G1 phase, which might be a result of extended G1 length when protein synthesis becomes limited in 
response to decreased nutrient availability rather than a cell cycle controlled event [95].  
 
 
Figure 6. Quiescence. Yeast cells can in response to nutrient limitation exit the mitotic cell cycle and enter a quiescent state of 
growth arrest in the G1 derived G0 phase. When conditions become favorable for growth, the cells reenter the cell cycle. Figure 
modified from Allen et al. (2011) [96]. 
 
Quiescent cells are characterized by their ability to maintain viability in a growth arrested state for 
extended periods of time. The overall metabolism of the cell is reduced as a consequence of inhibition of 
translation initiation [97], reduced expression of ribosomal proteins [98,99], and repressed transcription by 
RNA polymerase II [100]. The quiescent cell state induces autophagy, a process by which the cell degrades 
non-essential cellular components to liberate metabolites under starvation conditions [94,101]. They also 
accumulate the carbohydrate trehalose for energy reserves [102] and increase fatty acid oxidation [103]. 
Furthermore, quiescent cells have a thickened cell wall and are tolerant to a variety of environmental 
stresses [94].  
It has previously been assumed that all cells in the stationary growth phase were in a quiescent state [99]. 
However, it has later become apparent that stationary phase populations are likely to contain a mix of 
quiescent and non-quiescent cells [96]. Quiescent cells are dense, unbudded daughter cells formed after 
the diauxic shift. They can survive prolonged starvation and synchronously reenters the mitotic cell cycle.  
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Because quiescence can be entered in all cell cycle phases and transcriptome and metabolome profiles are 
specific for the inducing stimuli, quiescence is not a unique state [104,105]. Heterogeneous quiescent 
states might also be influenced by time-spent in growth arrest [104]. Non-quiescent cells are a 
heterogeneous population of replicative older cells that have lost the ability to reproduce and increase 
apoptosis during starvation [96,106].  
Quiescent cells are poised for immediate response and rapid resumption of proliferation when conditions 
become favorable. RNA polymerase II is prepared to activate the transcription machinery by being located 
upstream of several genes that are inactive during quiescence, but are required for cell proliferation [99]. 
Furthermore, actin bodies and long term polarity cues are located at one cell pole, which ensure efficient 
initiation of polarized cell growth [107,108]. Re-suspending quiescent cells in nutrient rich media stimulate 
exit from quiescence and entry to the mitotic cell cycle after activation of protein synthesis [94]. Addition of 
metabolites like glucose activate mobilization of actin bodies and have been shown to be sufficient to 
trigger exit from quiescence without inducing growth [95]. Vacuolar membrane associated proteins 
belonging to the EGO complex ensure proper exit from G0 [109] possibly by activation of the TORC1 
pathway [110].  
 
4.4 Nutrient sensing and growth control 
 
TOR pathway 
Cell growth control in response to nutrient availability is regulated by Target of Rapamycin (TOR). TOR is a 
highly conserved protein kinase belonging to the Ser/Thr family that in yeast forms two protein complexes 
called TOR complex 1 (TORC1) and TOR complex 2 (TORC2).  
TORC1 is primarily located at the vacuolar membrane [111]. When nutrients are abundant, TORC1 
positively controls ribosome biogenesis by activation of translation initiation factors, ribosomal protein 
transcription factors and RNA polymerases I, II and III [111,112]. The downstream effect of TORC1 
activation is protein synthesis that facilitates cell proliferation (Figure 7). Additionally, TORC1 regulate cell 
cycle transition by activation of cyclin kinases [111]. In addition to promoting anabolic processes, TORC1 
also stimulates growth by inhibiting catabolic processes associated with stress survival. Stress response 
programs in yeast, like the ESR, autophagy and the cell wall integrity pathway, have an inhibitory effect on 
growth, and are therefore suppressed by TORC1 in benign environments to ensure optimal growth 
[101,111]. TORC1 also regulates localization and expression of nutrient permeases for utilization of 
preferred nutrients sources before non-preferred [111].  
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Figure 7. TOR. The TOR protein complexes control the balance between cell growth and stress survival. In the presence of good 
quality nutrient sources, TOR activates protein synthesis and inhibits transcriptional stress responses and autophagy. Nutrient 
starvation blocks TOR and results in growth arrest and induced stress response. Figure adapted from Raught et al. (2001) [113]. 
 
When the cell is starved for glucose or nitrogen, TORC1 becomes inhibited and the cell arrests growth. A 
similar response can be observed when the cell is treated with the immunosuppressive drug rapamycin 
[114]. Rapamycin form a complex with the protein FKB12 that inhibit the activity of TORC1 [115] and 
rapamycin treatment is responsible for the extensive knowledge available for TORC1 function. 
TORC2 is insensitive to rapamycin and because no TORC2-specific inhibitor has been identified, much less is 
known about this protein complex. TORC2 is located at the plasma membrane and regulates cell polarity 
and endocytosis. TORC2 controls cell growth by actin cytoskeleton mediated supply of proteins and lipids to 
the proliferating daughter cell [101,111]. Additionally, TORC2 is involved in lipid homeostasis and is a 
positive regulator of sphingolipid biosynthesis [111,116].   
 
PKA and SNF1 
Nutrient sensing in yeast is very complex with multiple overlapping nutrient sensing pathways [101,117]. S. 
cerevisiae has besides TOR two other major nutrient sensing kinases that respond to nutrient availability, 
namely Protein Kinase A (PKA) and SNF1. PKA regulates cell growth in response to glucose and is required 
for the cell to execute START in the cell cycle while inactivation of PKA results in cell cycle arrest [117].  
The SNF1 network regulates genes required for growth on non-preferred fermentable and non-fermentable 
carbon sources, and SNF1 is therefore required to achieve a stable growth arrested state [94].  
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5. Future treatment options 
The major concerns in the hospital sector regarding fungal infections are the increasing numbers of 
patients susceptible to fungal infections, the more frequent isolation of azole resistant Candida species and 
the poor activity of conventional systemic antifungal agents against fungal biofilms. Although several 
second-generation triazoles and new echinocandins recently have been developed, new drugs with novel 
modes of action are limited for antifungal therapy (Figure 8). There is a demand for development of novel 
antifungal therapies, but the high similarity between fungi and humans limits the number of unique 
antifungal targets and can cause severe toxic side effects [44]. 
 
 
Figure 8. Antifungal drug development. No new major antifungal drug class that later has been introduced to clinical practice has 
been identified since 1972. Figure adapted from Butts and Krysan (2012) [118]. 
 
One approach to discover novel antifungal agents is to screen libraries of natural products or synthetic 
chemical compounds for antifungal activity [118]. Accordingly, natural oils with Candida inhibitory activity 
and anti-biofilm activity have been identified with monotherapy potential [119-121]. Synergistic activity 
between conventional antifungal agents and unrelated compounds has shown the possibility of new drug 
combination therapies against yeast biofilms [122-124]. Targeting virulence mechanisms such as biofilm 
formation is an alternative to inhibit essential cellular processes. Biofilm prevention and biofilm dispersion 
are suggested targets that can be achieved by use of prophylactic treatment, blocking QS signaling or 
dissolving extracellular matrix [73,125]. Biofilms are known for the existence of slow growing or growth 
arrested cells that can tolerate high concentrations of antimicrobial agents. Treatment targeting genes 
responsible for this phenotype might cause eradication of the entire cell population if it is combined with 
conventional antifungal agents [126,127]. Alternatively, stimulating exit from quiescence and increase 
metabolic processes that facilitate antifungal drug activity without inducing cell growth might be a future 
treatment strategy [95,128,129].        
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5.1 Antimicrobial peptides 
Antimicrobial peptides (AMPs) have attracted a lot of attention in the past decades as a source for future 
drug discovery. AMPs are generally described as small (12-50 amino acids), cationic and amphipathic 
peptides that are part of the innate immune system of plant and animal species [130,131]. The 
physiochemical properties of AMPs facilitate membrane permeability and rapid cell lysis, but they can also 
target intracellular processes by inhibiting synthesis of DNA and proteins [132]. Several AMPs have a broad 
spectrum of activity and targets both bacteria and fungi, hence AMPs that exclusively targets fungi are less 
common than those with broad antimicrobial properties [131]. The commercial most successful antifungal 
peptides are members of the echinocandin family that presently are the only peptides with FDA approved 
use against systemic mycosis [131]. Other antifungal peptides include plant defensins and histatins but 
most of them have poor pharmacokinetic or pharmacodynamic properties [130,131]. The advantage of 
AMPs as therapeutic drugs is their novel mechanisms of action that make them active against strains that 
are resistant to the commonly used antifungals. It has also been suggested that the rapid killing kinetics and 
unspecific mechanism of action decrease resistance development, although resistance to AMPs have been 
observed [133]. The membrane permeabilizing AMPs are attractive candidates for anti-biofilm therapy 
because they can kill slow growing and growth arrested cells [130]. The disadvantages of naturally 
occurring peptides are loss of activity in vivo due to the presence of biological body fluids and proteolytic 
degradation, toxic side effects, rapid clearance and high production cost [130].      
The drawbacks of natural AMPs can be overcome by chemical alterations of backbone and side chains that 
mimics the structure and function of natural peptides. Recent advances in organic chemistry have led to 
the development of systematic tools that, guided by rational design and molecular modeling, create a 
platform for future drug discovery. Because of inexpensive oligomers for de novo synthesis, 
peptidomimetics with protease stability can be produced at low cost [134,135]. Based on structure-activity 
relationship, antifungal activity and bioavailability can be optimized for therapeutic use [135].   
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6. Saccharomyces cerevisiae as a model organism 
Saccharomyces cerevisiae (S. cerevisiae) is a species of yeast that is also known as baker’s yeast or budding 
yeast. The fermentation properties of S. cerevisiae have been used for baking, beer and wine production 
since ancient time [136,137] and it is today one of the most extensively studied organisms. S. cerevisiae has 
a genome size of 12Mb with ~6000 genes (~1000 essential [138]) organized on 16 chromosomes [139]. It 
can be haploid or diploid containing one or two homologous copies of each chromosome, respectively.  S. 
cerevisiae has a cell size of 5-10 µm and reproduces by mitosis, which is an asexual division where the 
daughter cell buds out from the mother [140]. Optimal growth conditions are anaerobically in rich medium 
with a carbon source, preferable hexoses like glucose and fructose, at 25-30°C, but it can grow at up to 
42°C [141]. Natural habitats of S. cerevisiae are sugar-rich fruits such as grapes, peaches and oranges [142-
144]. Because S. cerevisiae is not airborne [145] and lack motility proteins similar to flagella and pili in 
bacteria, it is being relocated by insects [146]. 
S. cerevisiae is a widely used model organism for several reasons. Besides its relatively high homology to 
human cells [147] and pathogenic yeasts [148], it is genetically tractable with high efficiency of homologous 
recombination and DNA transformation [149,150] allowing easy and cheap genetic manipulations [147]. 
Furthermore, S. cerevisiae has a fast growth rate and it was the first eukaryotic genome that was 
sequenced [139]. This has made S. cerevisiae the favored eukaryotic organism for the application of novel 
methods such as transcriptomics [151] and proteomics [152]. Since the 1990s, several genetic and 
bioinformatic tools have been developed in yeast for the study of biological functions of genes and how 
they interact [153]. Gene interactions and genotype to phenotype correlations can experimentally be 
studied in S. cerevisiae using methods such as synthetic genetic array (SGA) [154] and multiplexed barcode 
sequencing (Bar-seq) [155]. 
 
6.1 S. cerevisiae biofilm 
While flocculation of S. cerevisiae is recognized as an important phenotype in the brewing industry that 
facilitate easy separation of yeast cells from the brew [156], it is not a desired trait in most microbiology 
laboratories because the flocculating lifestyle interferes with common cultivation and genetic assays. It is, 
however, important in the study of biofilm formation. Although S. cerevisiae was suggested as a model 
organism to study yeast biofilms more than a decade ago [3] not much progress have been made to 
develop and explore S. cerevisiae biofilm abilities and take advantage of all the molecular and genetic tools 
available for this organism compared to the pathogenic yeasts. Interestingly, C. glabrata is phylogenetically 
more closely related to S. cerevisiae than to other Candida species [157] and it has only been isolated as 
haploids with yeast morphology, which is in contrast to filamentation associated with C. albicans virulence 
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[158]. It has furthermore been shown that S. cerevisiae and C. glabrata have homologs in environmental 
stress response [159] and S. cerevisiae might therefore be a particularly good model for C. glabrata 
biofilms. Most importantly, S. cerevisiae possesses all the common traits that are associated with biofilm 
formation by Candida species. 
 
Cell-surface adhesion 
Attachment of S. cerevisiae cells to foreign surfaces is dependent on the cell surface protein Flo11 and 
deletion mutants are unable to from a biofilm [3]. FLO11 is a homolog to the ALS and EPA gene family 
adhesins in Candida species [160]. Expression of FLO11 is regulated by a complex network involving several 
major pathways in S. cerevisiae metabolism [161]. Stressful conditions such as starvation from glucose, 
nitrogen or amino acids is known to induce FLO11 expression [156,161]. The FLO11 gene is also responsible 
for other phenotypes in yeast that resembles biofilm formation, such as flocculation [162], invasive growth 
[163], pseudohyphae [164] and flor development [16]. Although S. cerevisiae have four other FLO adhesins 
(FLO1, FLO5, FLO9 and FLO10) most laboratory strains only express FLO11 while the others remain 
transcriptionally silent [165,166].  
 
Extracellular matrix 
S. cerevisiae cells growing as flocculating multicellular consortia in liquid media or as colonies on solid agar 
have by electron microscopy been shown to produce an extracellular matrix that encapsulate the cells. 
[167-170]. The extracellular matrix can be visualized as a dense layer around the cell wall, but is not part of 
the cell wall itself [168]. The extracellular matrix has been found to contain polysaccharides, mainly 
hexoses, and monosaccharides such as glucose and mannose [168]. Proteins unrelated to flocculins have 
also been isolated [167]. Production of an extracellular matrix in S. cerevisiae is dependent on the 
expression of FLO genes, but it is not essential for flocculation [168]. 
 
Quorum sensing 
S. cerevisiae uses the QS molecules tryptophol and phenylethanol to activate FLO11 expression [171] and 
they are therefore likely to influence S. cerervisiae biofilm development. Tryptophol and phenylethanol are 
aromatic alcohols that are structurally related to the Candida albicans QS molecule tyrosol [172]. 
 
Antifungal tolerance 
Activity of clinical relevant antifungals against S. cerevisiae is not well studied probably because S. 
cerevisiae is not a pathogen. Therefore, the research on antifungal tolerance of biofilms formed by baker’s 
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yeast is also limited. However, S. cerevisiae cells in a biofilm have been found to decrease susceptibility to 
disinfectant biocides [173] and antifungals [174], suggesting that S. cerevisiae biofilms have the common 
traits of stress tolerance that are observed in pathogenic yeasts. 
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7. Present investigations 
Yeast biofilm cells are accredited for tolerating antimicrobial agents at concentrations that are up to 1000-
fold higher than their planktonic counterparts [175]. Several studies have observed this by comparing 
minimal inhibitory concentrations (MIC) of planktonic cells with drug susceptibility of mature (48 hours) 
biofilms [17,78,174,176]. Based on this, tolerance is suggested to be biofilm-specific. One major concern 
when comparing the two susceptibility assays is the incubation time before the cells are exposed to 
antifungal agents. In vitro standard MIC assay of planktonic cells are defined by the use of fresh cultures 
with low cell densities and fast growth [177]. Antifungal susceptibility against biofilm cells often involves 48 
hour cultures with high cell densities and slow growth [178]. By examining drug susceptibility under such 
distinct cultivation conditions, it can be expected that factors such as cell density, cell age and growth rate 
that are all unrelated to biofilm mode of growth per se, will mask true biofilm-specific tolerance 
mechanisms. These are all factors that are well described to also influence stress survival of planktonic cells 
[63,80,91,179] and can therefore be considered as artifacts of incubation time. It might be that the 
incubation time shapes the developing biofilm, but so will 48 hours growth of planktonic cells that in this 
time span have passed the diauxic shift and are about to enter stationary phase in nutrient rich media 
[180]. A 1000-fold increased tolerance to antimicrobial agents has also been reported for bacteria when 
comparing biofilm to planktonic cells. However, bacterial populations of biofilm and planktonic cells show 
similar tolerance to antimicrobial treatment when they have been cultivated under similar conditions, 
suggesting that planktonic cells can be just as tolerant to antimicrobials as biofilm cells [181-184]. To date, 
it has not been investigated if this also applies for fungal cells. In the experimental work presented in this 
thesis we cultivated biofilm and planktonic cells similarly to identify true yeast biofilm-specific tolerance 
mechanisms. The only difference was that the biofilm cells were grown on plastic surfaces to promote 
biofilm growth [3], while planktonic cells were grown in glass tubes that are incompetent for biofilm growth 
[185]. 
 
In the second part of this thesis we aimed to investigate the antifungal mechanism of action of a novel 
peptidomimetic called LTX-109. This drug has therapeutic potential as an alternative to the conventional 
antifungals in treatment of biofilm cells. LTX-109 was developed by the Norwegian pharmaceutical 
company Lytix Biopharma and it is currently in clinical phase II trials for topical treatment of bacteria. LTX-
109 is a tripeptide based on the pharmacophore of bovine lactoferricin. It contains a modified tryptophan 
residue (tertbutyl tryptophan) and is capped by an ethylphenyl group at the C-terminal [186].  The small 
molecule size of LTX-109 and synthetic modifications makes it tolerant to proteolytic cleavage and cheap to 
produce [186,187]. LTX-109 disrupts the bacterial cell membrane and has low toxicity against mammalian 
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cells [186]. Furthermore, LTX-109 has activity against multiresistant bacterial strains [188] and derivatives 
have shown anti-biofilms activity [189].  
 
We have in this thesis used the genetic tractable S. cerevisiae as a model organism for the pathogenic 
Candida species. A major advantage of using S. cerevisiae as a model system is the molecular tools 
developed for this organism, such as the barcoded gene deletion collection. Soon after the S. cerevisiae 
genome was published, a collaboration of European and North American laboratories finished the 
construction of a mutant library with deletions in 96% of all non-essential genes of S. cerevisiae [138,190]. 
A two-step PCR strategy that takes advantage of the high rate of homologous recombination in yeast was 
used to switch the gene of interest with a kanamycin resistance gene cassette (KanMX). Twenty-base 
oligomers with unique sequences for each mutant were simultaneously introduced up- and downstream 
the KanMX cassette equipping each mutant with molecular barcodes that can identify individual mutants in 
a pooled collection [138,190]. Together with the advances of next-generation sequencing, the mutant 
collection gives the opportunity to investigate thousands of strains simultaneously by screening the mixed 
population. Using multiplexed PCR strategies, the costs and labor can be reduced by amplification of 
barcode tags and incorporation of unique index sequences to each sample [155,191]. The gene deletions 
with associated barcodes can today be found in several strains and they were recently transferred to a 
biofilm competent strain [15]. This deletion collection provides a powerful tool to investigate the molecular 
basis for fungal biofilm development and drug tolerance.        
 
7.1 Aim of study 
The major objective of this thesis has been to investigate the multidrug tolerance mechanisms of yeast 
biofilm cells using S. cerevisiae as a model organism. Major emphasis has been on identifying true biofilm-
specific tolerance mechanisms that are a result of the biofilm mode of growth and not artifacts of extended 
incubation time. Furthermore, we investigated the mechanism of action of a novel antifungal 
peptidomimetic to identify a new target, which potentially could be used in future antifungal therapy.   
 
7.2 Overview of results 
This section provides a short summery of the results obtained during the work on this thesis. A more 
comprehensive description of methods, results and figures can be found in the research papers listed in 
section 10. 
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Paper 1| Yeast biofilm tolerance towards systemic antifungals depends on growth phase. 
In the first paper, we examined the susceptibility of yeast biofilm cells towards antifungal agents 
representing each of the four major drug classes currently used in systemic treatment of mycosis. This 
allowed us to investigate multidrug tolerance that covered the entire spectrum of clinically available drugs. 
Our results showed that flucytosine, the azole voriconazole, and the echinocandin caspofungin were 
inactive against 48 hours old biofilm for both C. glabrata and S. cerevisiae, while the polyene amphotericin 
B was the only tested drug with anti-biofilm activity. The results were compared to planktonic S. cerevisiae 
cells grown under similar conditions to investigate if the high tolerance levels were a unique trait for biofilm 
cells. We found that free-floating wild type cells and biofilm deficient flo11 knockout mutants cultivated for 
48 hours before drug exposure achieved the same level of antifungal tolerance as mature biofilm cells. 
These data showed that the observed antifungal tolerance was independent of planktonic or biofilm mode 
of growth.  
A high proportion of the biofilm cells had decreased metabolic activity and limited growth after 48 hours in 
our biofilm model system, which confirms previous studies [192-195]. In order to obtain comprehensive 
knowledge on how cell proliferation affects the activity of each antifungal agent, killing kinetics of each 
drug were investigated in exponential and growth arrested planktonic populations. We found that S. 
cerevisiae cells could grow in the presence of voriconazole, which can be attributed to a process known as 
trailing. Flucytosine was found to be fungistatic, caspofungin killed the majority of yeast cells and 
amphotericin B was fungicidal against exponential growing S. cerevisiae. However, only amphotericin B had 
antifungal activity against growth arrested cells similar to what was observed in the mature biofilms. These 
results showed that antifungal activity of the tested drugs was highly dependent on growth phase.  
Finally, we investigated the antifungal activity against proliferating biofilm cells and observed antifungal 
activity of all tested drugs similar to the killing kinetics study of exponential phase planktonic cells. These 
results demonstrated a strong correlation between growth activity of biofilm cells and drug treatment 
efficacy. The results were not surprising though, considering that fungistatic drugs and caspofungin targets 
biosynthetic pathways that are most active during cell growth and they will therefore not be expected to 
have activity against growth arrested cells in mature biofilms. 
 
Paper 2| Cellular state determines amphotericin B tolerance in yeast biofilm and planktonic populations. 
Slow growth was one of the first suggested tolerance mechanisms of biofilm cells [196] and, although a lot 
of research has been performed to discover additional tolerance mechanisms, it may still be the most 
pronounced contributor to antifungal recalcitrance. In paper 1 we showed that amphotericin B killed 
growth arrested cells, but was unable to eradicate the entire population of mature biofilm cells. So even 
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though slow growth seems like an appealing and simple explanation, it is insufficient to cover the 
amphotericin B tolerant subpopulation of mature biofilm cells.  
To characterize the molecular mechanisms underlying amphotericin B tolerance, we performed a screen of 
a pooled collection of deletion mutants cultivated as biofilm or planktonic cells treated with amphotericin 
B. Surviving cells were outgrown to enrich for viable cells and genomic DNA was purified. Molecular 
barcodes that uniquely identifies each mutant were amplified and sequenced. We found that errors in four 
major biological processes could result in increased amphotericin B survival. Not surprisingly, defects in 
lipid metabolism increased amphotericin B survival probably because of decreased drug-target affinity 
caused by cytoplasmic membrane alterations. We furthermore found that gene deletions in intracellular 
transport, protein synthesis and cell cycle processes resulted in increased viability after amphotericin B 
treatment. Because protein synthesis and cell proliferation is controlled by the TOR pathway [101], we 
inhibited TORC1 by rapamycin treatment of wild type cells and observed that it caused a ~500-fold increase 
in amphotericin B survival compared to rapamycin untreated cells. These data suggested that the 
amphotericin B tolerant subpopulation was in a quiescent state that was physiological distinct from the 
sensitive subpopulation.  
Our results showed that defects in the same biological processes resulted in increased survival to 
amphotericin B treatment regardless of cells were cultivated as biofilm or planktonically. This strongly 
suggested that it was not the biofilm mode of growth per se that caused antifungal drug tolerance, but 
rather it was a result of the physiological state of the cell that can be induced in both modes of growth. 
 
Paper 3| The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma 
membrane integrity in a sphingolipid dependent manner. 
It can be a major challenge to target all heterogeneous subpopulations that are expected to be present in 
biofilms because of the limited number of antifungals with unique mechanisms of action. There is therefore 
a need for development of new fungicides with novel mechanism of action that can be used to supplement 
the commonly used antifungals.  
In paper 3 we sought to describe the mechanism of action of the novel peptidomimetic LTX-109. We found 
that LTX-109 rapidly killed exponential growing S. cerevisiae cells, which was associated with an almost 
immediate release of protons, potassium and amino acids to the extracellular environment. We 
furthermore observed that LTX-109 treated cells readily took up a 600-Dalton fluorescent reporter 
molecule that only penetrates cytoplasmic membrane compromised cells. These data strongly suggested 
that LTX-109 targeted the plasma membrane and caused rapid cell lysis, rather than inhibited an 
intracellular pathway. To identify a potential molecular target of LTX-109, we screened a mixed population 
of yeast deletion mutants on agar plates containing the drug and sequenced the barcode tags of resistant 
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mutants. We found that deletion of genes in the sphingolipid biosynthesis pathway resulted in LTX-109 
resistance, demonstrating an essential function of complex sphingolipids in LTX-109 fungicidal activity. 
These results indicated that LTX-109 destabilized the plasma membrane through direct or indirect 
interaction with the sphingolipids. We furthermore illustrated the potential use of LTX-109 for treatment of 
biofilm associated infection by showing that LTX-109 had anti-biofilm activity. 
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8. Conclusions and perspectives 
Knowledge about the molecular mechanisms underlying tolerance of yeast biofilm cells to antifungal agents 
is important for development of novel treatment strategies. Multidrug tolerance of yeast biofilms does not 
seem to be solely mediated by individual mechanisms. As such, increased efflux pump activity only 
facilitates transport of azoles, while the other drugs are not substrates to any known efflux pumps. It has 
furthermore been shown that the antifungal agents can penetrate the extracellular matrix layer that 
encapsulates biofilm cells and it is the general consensus that the matrix layer does not contribute 
significantly to long-term antimicrobial treatment [73]. The close proximity of bacterial cells in biofilms 
have been suggested to facilitate a high rate of horizontal transfer of resistance genes [73], but acquisition 
of external DNA does not occur in intact yeast cells [57]. Finally, it has been observed that bacterial biofilm 
cells have an increased mutation rate that can result in development of antimicrobial resistance [73], but, 
except for flucytosine, antifungal resistance is a rare event in pathogenic fungi. Cross-resistance to multiple 
drugs is even more unlikely, because there are no multidrug resistance mechanisms in yeast that apply to 
all systemic drug classes. Cross-resistance should then evolve as a result of two independent mutations in 
two specific and unrelated genes with the possible exception of azoles and polyenes that are both 
dependent on ergosterols. Antifungal recalcitrance of biofilm cells are most likely mediated by non-
inherited mechanisms as a result of physiological population heterogeneity. 
We showed in paper 1 how antifungal drug activity was correlated with growth phase by testing the 
inhibitory efficacy against yeast populations with mainly growth arrested cells and against populations with 
mainly proliferating cells. A real life biofilm might consist of both growing and non-growing cells, but as 
long as they contain non-growing cells, the majority of antifungal agents currently used in the clinic are 
expected to be inactive against this subpopulation. Despite the possible influence of other factors, slow or 
no growth can alone explain the poor antifungal activity of most antifungal drug classes against biofilm 
cells. In addition to growth arrest, we found in paper 2 that defects in protein synthesis, intracellular 
transport, mitotic cell cycle and lipid metabolism resulted in increased survival of cells exposed to 
amphotericin B. This could be the result of stochastic events that caused fluctuations and variability in 
cellular processes such as DNA replication, cell membrane potential, ribosome activity and cytokinesis. We 
furthermore found that amphotericin B survival could be enhanced by nutrient starvation or inhibition of 
nutrient sensing pathways.  
We have shown that planktonic cells can achieve a tolerance level similar to biofilm cells if they were 
cultivated in the same medium and for equally long time. We furthermore demonstrated that decreased 
metabolism, reduced growth rate and defects in the same biological processes were shared tolerance 
mechanisms between the two modes of growth. We conclude that antifungal tolerance is the combined 
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result of the mode of action of the antifungal agents and the physiological state of the cell. We suggest that 
growth in a nutrient limited environment for 48 hours induce a stress response resulting in acquired 
antifungal drug tolerance and that this can explain the enhanced tolerance levels observed in biofilm cells. 
Due to the difficulty in diagnosis of biofilm infections and the observation that biofilm and planktonic cells 
respond similarly to antifungal treatment, it can be suggested that development of novel treatment 
strategies should target growth arrested cells without distinguish between sessile and free-floating cells. 
One approach could be to stimulate exit from quiescence, which have been shown to be initiated by 
exposure to metabolites without resulting in cell proliferation [95]. This might restore the activity of the 
systemic drugs that are inactive against quiescent cells. Another approach is to develop novel antifungal 
agents that target growth arrested cells for monotherapy or in combination with the conventional systemic 
drugs. Targeting extracellular components such as cell wall synthesis or cytoplasmic membrane 
components are obvious targets for novel antifungal agents, because they are likely to have fungicidal 
properties and they are not expected to be substrate to multidrug transporters. In paper 3 we identified 
sphingolipids as a novel antifungal target. Several natural peptides also inhibit the sphingolipids [197] and 
they are promising targets for future drug development because they are highly conserved among fungi, 
but distinct in human cells. Finding specific treatment against biofilm cells might only be relevant for 
treatment of catheter-related infections to which the surface attached property of biofilm cells 
undoubtedly is a biofilm-specific trait.  
The data presented in this thesis rely on the value of S. cerevisiae as a model organism for the pathogenic 
Candida species. S. cerevisiae as a model might be limited because of its non-pathogenic behavior and 
because it has evolved under environmental conditions that are different from the natural habitats of 
Candida species. The findings in this thesis should therefore be confirmed in pathogenic yeasts. Our results 
from paper 1 indicate that S. cerevisiae and C. glabrata biofilms have similar antifungal sensitivity, but a 
more thoroughly experimental comparison needs to be performed to verify this. 
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ABSTRACT 22 
Biofilm-forming Candida species cause persistent infections that are difficult to eradicate, possibly 23 
because of antifungal drug tolerance mechanisms specific to biofilms. We used Saccharomyces cerevisiae 24 
as a model for drug susceptibility of yeast biofilms. Confocal laser scanning microscopy showed that S. 25 
cerevisiae and C. glabrata form similarly structured biofilms and that the viable cell numbers were 26 
significantly reduced by treatment of mature biofilms with amphotericin B but not voriconazole, 27 
flucytosine, or caspofungin. We showed that metabolic activity in yeast biofilm cells decreased with time, 28 
as visualized by FUN-1 staining, and mature, 48-hour biofilms contained cells with slow metabolism and 29 
limited growth. Time-kill studies showed that in exponentially growing planktonic cells, voriconazole had 30 
limited antifungal activity, flucytosine was fungistatic, caspofungin killed the cells, and amphotericin B 31 
was fungicidal. In growth-arrested cells, only amphotericin B had antifungal activity. Confocal 32 
microscopy and colony count viability assays revealed that the response of growing biofilms to antifungal 33 
drugs was similar to the response of exponentially growing planktonic cells in time-kill studies and 34 
mature biofilm was similar to non-growing planktonic cells. These results confirmed the importance of 35 
growth phase on drug efficacy. In conclusion, we showed that in vitro susceptibility to antifungal drugs 36 
was independent of biofilm or planktonic growth mode. Instead, drug tolerance was a consequence of a 37 
physiological cell state achievable by both planktonic and biofilm populations. Based on our results, drug 38 
treatment strategies should target non-dividing cells rather than focusing on biofilm-specific tolerance 39 
mechanisms.   40 
3 
 
INTRODUCTION 41 
Nosocomial fungal infections are an increasing problem for immune compromised patients with severe 42 
underlying disease
1
. Fungi can colonize mucosal surfaces in the oral cavity, airways, wounds and the 43 
gastrointestinal tract, causing chronic infections
2
. Fungi can also adhere to invasive medical devices and 44 
cause severe septicemia
3
. It is thought that many chronic human infections are associated with the 45 
formation of microbial biofilms
4
. The hallmarks of biofilms are surface attachment and production of an 46 
extracellular matrix (ECM)
5
. Failure to eradicate chronic infections is often attributed to the unique 47 
lifestyle of cells in biofilms and it is widely accepted that cells in a biofilm possess antimicrobial 48 
tolerance mechanisms that are distinct from their planktonic counterparts. However, in spite of decades of 49 
research, the molecular mechanisms responsible for biofilm-specific drug tolerance are not fully 50 
elucidated
6
. 51 
Drugs currently being used to treat systemic mycoses belong to four major classes. The azoles target 52 
cytochrome P450 and inhibit cell membrane ergosterol biosynthesis, resulting in accumulation of toxic 53 
ergosterol intermediates
7
. The echinocandins inhibit 1,3-β-glucan synthases, resulting in a reduction in 54 
cell wall 1,3-β-glucan8, and the polyenes target ergosterol and cause pore formation in the fungal cell 55 
membrane
9
. The fourth class is the antimetabolite flucytosine. Flucytosine is deaminated upon uptake in 56 
susceptible cells and converted to 5-fluorouridine triphosphate, which is incorporated into RNA, 57 
inhibiting protein synthesis
10
. Flucytosine can also be converted to 5-fluorodeoxyuridine monophosphate 58 
which acts on thymidylate synthase to inhibit DNA synthesis
10
. Despite the pronounced diversity in 59 
antifungal mechanism of action, most antifungal agents are inactive against fungal biofilms. 60 
Several mechanisms have been suggested to be responsible for drug tolerance of yeast biofilms, but none 61 
of them can solely account for the multidrug tolerance associated with biofilms. The contribution of the 62 
ECM to antifungal drug recalcitrance is not fully understood. Although some antifungal drugs bind to 63 
ECM components they can still diffuse through the matrix layer in inhibitory concentrations
11-13
. The 64 
ECM, in combination with the nutrient-limited environment that results from a large number of microbial 65 
cells, might induce expression of genes that help cells cope with stressful conditions. Altered gene 66 
expression could involve differential regulation of general stress-response genes that affect drug 67 
tolerance. For example, efflux pumps are reported to be upregulated in young
14
 and intermediate
15
 68 
biofilms in Candida species. However, efflux pump knockout mutants remain drug resistant
14, 16
 and up-69 
regulation is lost in mature biofilms
14, 15
. Furthermore, since polyenes and echinocandins are not a 70 
substrate of any known efflux pumps
17
, efflux pumps are not solely responsible for biofilm-mediated 71 
tolerance to these drug classes. Decreased levels of drug target molecules are reported in maturing 72 
4 
 
Candida spp. biofilms
14, 18
, but not for all drug classes. It might be a combination of several individual 73 
mechanisms that cause multidrug tolerance in yeast biofilms. Biofilms consist of heterogeneous 74 
populations of phenotypically diverse cells. This heterogeneity is caused by the nonuniform and 75 
structured environment of the biofilm
19
. To be effective against biofilms, an antifungal drug must target 76 
all of the multiple subpopulations in the biofilm.  77 
Fungal and bacterial research report 1000-fold higher tolerance level of mature biofilms compared to 78 
proliferating planktonic populations
20, 21
. However, research in bacteria has shown that the tolerance 79 
phenotype is similar between biofilm and planktonic cells when grown to stationary state 
22-24
. This 80 
indicates that tolerance mechanisms are not biofilm-specific and that planktonic cells can achieve the 81 
same level of tolerance. To date, comparison between biofilms and planktonic cells cultivated under 82 
similar conditions has not been performed in yeast.  83 
C. glabrata is the second most-frequent cause of candidemia
25
 and is phylogenetically more closely 84 
related to Saccharomyces cerevisiae than to other Candida species
26
. The biofilm structure of C. glabrata 85 
is also more similar to S. cerevisiae than to C. albicans. C. glabrata form a thin layer of biofilm that 86 
contain haploid blastospores and lack hyphae and pseudohyphae morphology that are characteristic to C. 87 
albicans biofilms
27, 28
. Furthermore, C. glabrata has environmental stress response homologs to S. 88 
cerevisiae
29
. S. cerevisiae has all the traits commonly associated with microbial biofilms and is more 89 
easily manipulated than C. glabrata
30
 making S. cerevisiae a relevant model for this pathogen. We used in 90 
vitro biofilms of S. cerevisiae and C. glabrata cultures to investigate antifungal tolerance to the major 91 
antifungal drug classes used for systemic treatment of human pathogenic fungal infections: the polyene 92 
amphotericin B (AmB), the azole voriconazole (VOR), the antimetabolite flucytosine (5FC), and the 93 
echinocandin caspofungin (CAS). We have in the present study performed a thoroughly study of the 94 
relation between the mechanism of action of the individual drugs and the drug tolerance level of yeast 95 
cells. To identify biofilm-specific mechanisms, free-floating planktonic cells were used for comparison. 96 
We found that the ability of biofilms to survive antifungal treatment was dependent on the mode of action 97 
of the antifungal agent and the metabolic state of the yeast cells.   98 
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MATERIALS AND METHODS 99 
Yeast strains: S. cerevisiae Σ1278b YS-11 (MATa can1Δ::STE2p-spHIS5 lyp1Δ::STE3p-LEU2 100 
his3::HisG leu2Δ ura3Δ) was used as reference strain (a gift from the Boone Laboratory, University of 101 
Toronto). A flo11 mutant that does not form biofilm was obtained from the Σ1278b gene deletion 102 
library
31
. C. glabrata (ATCC 90030) was obtained from the American Type Culture Collection. A strain 103 
expressing green fluorescent protein (GFP) was constructed by expressing the GFP gene from the TEF1 104 
promoter. The TEF1 promoter was PCR amplified from pSP-GM2
32
 with primers 5’-105 
CGTGCGAUGCCGCACACACCATAGCTTC and 5’-106 
ACGTATCGCUGTGAGTCGTATTACGGATCCTTG. GFP was amplified from pJBA27a
33
 with 107 
primers 5’-AGCGATACGUAGCATGCGTAAAGGAGAAGAA and 5’-108 
CACGCGAUTATTTGTATAGTTCATCCATGCC. The GFP and TEF1 DNA fragments were 109 
assembled with USER technology
34
 and inserted into vector pXI-2
35
 digested with AsiSI and nicking 110 
enzyme Nb.BsmI and transformed into competent Escherichia coli (DHα5) as previously described36. The 111 
PTEF1-GFP fragment was inserted in chromosome XI position (91,575..92,744) of the reference strain 112 
using a high-efficiency transformation protocol
37
 and selected on uracil depleted agar. 113 
 114 
Media and antifungals: All experiments were performed in synthetic medium (0.67% yeast nitrogen 115 
base supplemented with glucose and amino acids)
38
. A 0.2% (w/v) glucose concentration was used in all 116 
biofilm experiments. Yeast extract peptone dextrose (YPD)
38
 agar plates were used for colony counting. 117 
Antifungals voriconazole, flucytosine, amphotericin B and caspofungin were from Sigma-Aldrich. All 118 
antifungals were dissolved in DMSO in 5 mg/ml stock solutions and stored at -20°C. All experiments 119 
were performed in triplicate. 120 
 121 
Minimal inhibitory concentration: Minimal inhibitory concentrations (MIC) were determined as 122 
previously described
39
 with modifications. In short, two-fold dilution series of antifungal drugs were 123 
prepared in fresh synthetic medium with 2% glucose (w/v) and distributed into 96-well microtiter plate. 124 
Visibly turbid overnight cultures were diluted to OD600 0.1 in fresh medium and transferred to microtiter 125 
plates containing aliquots of serially diluted antifungal drug. Plates were statically incubated at 30°C for 126 
24 h and absorbance was measured with a microplate spectrophotometer (BioTek PowerWave 340). 127 
Growth inhibition of ≥ 50% was determined as MIC for CAS, VOR and 5FC and ≥ 90% growth 128 
inhibition was determined as MIC for AmB as recommended by EUCAST
39
. 129 
 130 
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Visualization of biofilm drug susceptibility: Visibly turbid cultures were diluted to OD600 0.1. After 2 131 
hours at 30°C, cells were transferred to biofilm chambers (Technical University of Denmark) with a 132 
polyvinyl chloride (PVC) coverslip surface (Rinzl, Electron Microscopy Sciences). After 4 or 48 hours 133 
static incubation at 30°C, medium was removed from biofilm chambers and centrifuged and antifungal 134 
drug was added to the supernatants at 10 times the MIC. Spent medium with drug was introduced to 135 
biofilm cultures followed by 24 hours at 30°C. Chromosomally integrated GFP and 3 µM Syto9 136 
(Invitrogen) were used to visualize live cells and 1 µM propidium iodide (PI, Sigma-Aldrich) was used to 137 
stain dead cells. Confocal laser scanning microscopy (CLSM) was performed with a Zeiss LSM710 138 
microscope equipped with excitation lasers at 488 nm and 514 nm. Imaging used an EC Plan-Neofluar 139 
40x/1.30 Oil lens. 140 
 141 
Metabolic activity: Preparation of cell cultures and CLSM imaging was as described above except a 142 
Plan-Apochromat 63x/1.40 Oil DIC M27 objective was used. Metabolically active cells were 143 
distinguished from inactive cells with 10 µM FUN-1 as described by the manufacturer (Molecular Probes, 144 
Probes for yeast viability, MP 07009). Cells were considered metabolic active if they produced red 145 
cylindrical intravacuolar structures
40, 41
.  146 
 147 
Killing kinetics: Overnight cultures were diluted to OD600 0.01 in fresh synthetic medium. Yeast cultures 148 
were grown to exponential phase in baffled shake flasks at 30°C and samples were distributed to test 149 
tubes for exposure to antifungal drugs at 5 times the MIC before incubation at 30°C with aeration. 150 
Samples were extracted at indicated time-points. Colony forming units (CFUs) were determined by 151 
plating serial dilutions on YPD agar. 152 
 153 
Antifungal survival assay: Visibly turbid cultures were diluted to OD600 0.1 in synthetic medium and 154 
grown in baffled shake flasks for 2 hours. Culture samples were distributed to glass tubes for planktonic 155 
cells and polystyrene microtiter plates for biofilms and incubated statically at 30°C. After 4 or 48 hours, 156 
cells were challenged with antifungal drug at 10 times the MIC, added in spent medium, for 24 hours. 157 
Viable cells were determined by counting CFUs on YPD agar. Biofilm cells were washed twice in saline 158 
and CFU was determined.  159 
 160 
Statistical analysis: Unpaired Student’s t-test was used for statistical analysis. P < 0.01 was considered 161 
significant.  162 
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RESULTS 163 
S. cerevisiae and C. glabrata biofilms have similar structure and antifungal tolerance  164 
Antifungal drug susceptibility of S. cerevisiae cells were similar to C. glabrata as determined by minimal 165 
inhibitory concentrations (MIC), except for voriconazole that was 4 mg/l against C. glabrata, and 1 mg/l 166 
against S. cerevisiae (Figure 1a). 167 
 168 
Yeast biofilm architecture and antifungal drug sensitivity was investigated using CLSM. Mature GFP-169 
tagged biofilm cells were challenged with an antifungal agent for 24 hours and stained with PI to mark 170 
dead cells. Untreated S. cerevisiae biofilms contained a thin layer of cells (approximately 30 µm) with a 171 
few dead cells distributed throughout the biofilm. Biofilms treated with VOR, 5FC, or CAS had the same 172 
architecture and mixture of living and dead cells as untreated control cells (Figure 1b), showing that the 173 
drugs were inactive against yeast biofilms. AmB was the only tested drug with anti-biofilm activity, 174 
killing most cells after 24 hours (Figure 1b). The small subpopulation of cells that survived AmB 175 
treatment was randomly distributed in the biofilms. 176 
To determine if results from the S. cerevisiae biofilm model applied to drug susceptibility in a pathogenic 177 
yeast, we investigated the antifungal drug susceptibility of C. glabrata biofilms. C. glabrata was 178 
cultivated under conditions similar to S. cerevisiae cultures and developed a thin layer of biofilm cells 179 
(approximately 25 µm). After 48 hours, mature biofilms were challenged with an antifungal drug for 24 180 
hours and stained with Syto9 and PI to visualize living and dead cells. Results were similar to those 181 
obtained with S. cerevisiae. Most C. glabrata biofilm cells exposed to VOR, 5FC or CAS showed living 182 
cells with a few dead cells distributed in the biofilm similar to the appearance of the untreated control 183 
cells (Figure 1b). AmB treatment killed most cells with a small, surviving subpopulation randomly 184 
distributed in the biofilm. These results suggested that S. cerevisiae could be used as a model organism to 185 
study antifungal tolerance in biofilms of the pathogenic C. glabrata. 186 
 187 
Metabolic activity of biofilm cells decreases with biofilm maturity 188 
Planktonic microbial cells cultivated in a closed system take up nutrients from the environment and enters 189 
a stationary growth state with decreased metabolic activity when nutrients become limited. To investigate 190 
if the metabolic activity of biofilms at 48 hours was reduced compared to a 4 hour biofilm, we measured 191 
metabolic activity using FUN-1 staining. FUN-1 permeabilizes the plasma membrane and biochemical 192 
processing of the dye by an unknown pathway identifies metabolically active cells with intravacuolar 193 
structures
40
. Most cells in a 4-hour biofilm showed high metabolic activity as estimated by staining 194 
intensity (Figure 2), but decreased with biofilm incubation time. After 48 hours, only a small 195 
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subpopulation of cells in the biofilms showed FUN-1 staining of vacuoles indicating a lower or different 196 
metabolic activity in mature biofilm than that found in young 4 hour biofilm (Figure 2).  197 
 198 
Activity of antifungal drugs depends on growth state 199 
We hypothesized that the limited metabolic activity observed in cells in mature biofilms may be an 200 
important cause of the low antifungal activity of the drugs tested. We measured therefore the killing 201 
kinetics of the antifungals using an exponentially growing planktonic population and a growth-arrested 202 
planktonic population. Untreated control cells proliferated with a doubling time of 1.5 hours in the 203 
exponential growth phase for the first 8 hours of incubation (Figure 3a). The density of cells exposed to 204 
VOR increased at the same rate as the untreated sample for the first 7 hours of incubation. Subsequently, 205 
the azole drug inhibited growth, resulting in a decrease in viability after 24 hours. After two hours of 206 
exposure to 5FC, the growth of exponential phase populations was inhibited and cells remained at the 207 
same viability and density for 24 hours showing that 5FC had fungistatic activity. CAS had an inhibitory 208 
effect on exponential growth within the first hours of exposure and a consistent killing rate throughout the 209 
experiment that resulted in a 10-fold reduction in CFU after 24 hours compared to the initial population. 210 
Challenging cultures with AmB rapidly decreased the viable population, reaching the lower detection 211 
limit for CFUs after 5 hours.  212 
We next investigated how growth arrest affect susceptibility to antifungal agents by incubating cells in 213 
carbon-depleted medium. Starting cell density was similar to the starting density used for time-kill studies 214 
on the exponential growing populations to eliminate cell numbers from affecting comparisons between 215 
the two experiments. Growth-arrested S. cerevisiae exposed to VOR, 5FC or CAS had viability similar to 216 
untreated control cells, showing that the drugs had no activity against non-growing cells in stationary 217 
phase (Figure 3b). Cells exposed to AmB were killed, but the killing rate was lower than the rate observed 218 
for exponentially growing cells. The lower detection limit for CFUs was not reached in the first 8 hours of 219 
drug exposure, but only after 24 hours.  220 
 221 
Drug sensitivity restored in a growing biofilm population 222 
The antifungal activity of 5FC, CAS and AmB against exponentially growing planktonic S. cerevisiae but 223 
not against growth-arrested cells suggested that drug activity depended on cell growth. To test if growth-224 
dependent drug activity also applied to cells in biofilms, the viability of a growing S. cerevisiae biofilm 225 
was quantified as CFUs and visualized with CLSM. Quantification and visualization assays were 226 
conducted after 24 hours of drug treatment. The number of cells in untreated 4-hour biofilms increased 8-227 
fold over 24 hours, as determined by CFUs (Figure 4). Growth in 4-hour biofilms exposed to VOR or 228 
5FC was inhibited compared to untreated control biofilms. Cell numbers determined by CFUs increased 229 
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3-fold with VOR treatment and 1.3-fold with 5FC treatment. In contrast, 80% of biofilm cells exposed to 230 
CAS were killed, with surviving cells sporadically distributed in the biofilm (Figure 4). AmB had a 231 
fungicidal effect on young biofilms, killing 99.7% of cells during a 24-hour exposure. Biofilms treated 232 
with AmB still contained minor surviving subpopulations (Figure 4). 233 
 234 
Mature biofilm and planktonic yeast have similar susceptibility to systemic antifungals 235 
We observed that most drug classes tested in this study were inactive against mature biofilms (Figure 1), 236 
but had activity against 4-hours biofilms (Figure 4), and that this might be correlated to the metabolic 237 
state of the cell (Figure 2). These data suggest that the physiological state of the cell in response to ceased 238 
proliferation, rather than a biofilm-specific response mediate drug tolerance in yeast biofilms.   239 
To determine the effect of biofilm formation on drug tolerance, we investigated differences in antifungal 240 
drug susceptibility between cells grown planktonically or in biofilms for 48 hours. S. cerevisiae biofilms 241 
were cultivated on flat polystyrene surfaces. For planktonic control populations, S. cerevisiae was 242 
cultivated in glass tubes
42
. An isogenic biofilm-deficient flo11 knockout mutant was included as a 243 
negative control for biofilm formation
43
.  244 
All three cultures, biofilm, flo11 control, and planktonic, were challenged for 24 hours with antifungal 245 
agents. No significant effects on CFUs were seen after treatment with VOR, 5FC, or CAS (Figure 5), 246 
indicating that S. cerevisiae was not susceptible to any of the drugs under any of the three growth 247 
conditions. Only treatment with AmB significantly decreased population sizes (P < 0.01, Student’s t-test). 248 
Exposure to AmB killed 95-98% of the yeast populations regardless of growth condition (Figure 5). 249 
However, in all three growth conditions, a subpopulation of 2-5% of cells survived drug treatment, so 250 
AmB was unable to eradicate the entire S. cerevisiae population.   251 
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DISCUSSION 252 
In the current study, we found that antifungal drug efficacy against yeast biofilm was dependent on cell 253 
growth. Only growing yeast cells were susceptible to growth inhibition by the fungistatic drugs VOR and 254 
5FC, and killing by CAS. However, yeast cells in both growing and stationary state were efficiently killed 255 
by AmB. We further observed that the effects of antifungals were independent of biofilm or planktonic 256 
modes of growth. 257 
Multidrug tolerance mechanisms in biofilms are suggested to include production of an ECM and a 258 
densely packed microbial structure that shields cells, preventing antimicrobials from reaching their 259 
targets. Cell-surface proteins in the Flo family are responsible for S. cerevisiae adhesion and ECM 260 
production is dependent on Flo expression. Flo11p is the only flocculation protein expressed in the 261 
Σ1278b S. cerevisiae strain and it is essential for biofilm formation43-46. We showed that a flo11 mutant 262 
has an antifungal tolerance phenotype that is similar to mature yeast biofilms (Figure 5). This finding 263 
suggests that flocculation and Flo11p-dependent matrix production are not obstacles for cell penetration 264 
by antifungal drugs. In agreement with this, systemic antifungals penetrate the ECM of Candida species 265 
biofilms at concentrations that exceed the MIC values and no correlation is observed between the amount 266 
of matrix produced and drug susceptibility
11, 47
. These findings indicate that matrix and biofilm formation 267 
have less of an influence on drug susceptibility than previously thought. Nonetheless, surface attachment 268 
and matrix production might still contribute to persistent infections by reducing pathogenic cell clearance 269 
from body fluids and killing by immune cells
48, 49
. 270 
Heterogeneous microbial biofilms often contain large subpopulations with low metabolic activity
41, 50
. We 271 
showed that the metabolic activity of most cells in yeast biofilms decreased as the biofilm matured 272 
(Figure 2) and we observed no increase in cell density in mature biofilms (Figures 5a). Therefore, large 273 
fractions of cells in mature biofilms are likely in a stationary state that reduces the susceptibility to the 274 
antimicrobials. Even though antimicrobial agents have diverse modes of action, most are dependent on 275 
active growth to kill cells
51
, which we confirmed in the present study. 276 
The drug 5FC has fungistatic activity against Candida species
52
. We found a similar fungistatic activity 277 
against proliferating S. cerevisiae Σ1278b planktonic and biofilm populations (Figure 3a and Figure 4). 278 
However, 5FC was inactive against mature biofilms and growth arrested planktonic cells (Figure 1b, 279 
Figure 3b and Figure 5a). This result is not surprising since fungistatic drugs do not kill cells but only 280 
inhibit proliferation. Therefore, the viability of high-density, nongrowing microbial populations such as 281 
mature biofilms or stationary phase planktonic cells is expected to be unaffected by treatment with 282 
fungistatic drugs.  283 
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Echinocandins have fungicidal activity against Candida species
53
 and we found that CAS killed 90% of 284 
exponential growing planktonic S. cerevisiae cells (Figure 3a) and 80% of proliferating biofilm cells 285 
(Figure 4). Despite the ability of CAS to kill exponentially growing yeast cells, CAS had no activity 286 
against mature biofilms (Figure 1b and Figure 5a). CAS inhibits 1,3-β-glucan synthase, which disrupt the 287 
yeast cell wall and result in osmotic stress and cell lysis
8
. However, the synthase is most active in growing 288 
cells
54, 55
, so CAS is unable to kill growth-arrested cells
53
 as we observed in this study (Figure 3b) 289 
including the cells in mature biofilms. 290 
The polyene AmB was the only drug tested in this study with activity against cells in mature biofilms 291 
(Figure 1b and Figure 5a) and growth arrested planktonic cells (Figure 3b). AmB binds to ergosterol in 292 
the cell membrane and form pores that increase the permeability of electrolytes and small molecules. Pore 293 
formation results in loss of membrane potential and eventually cell lysis
9
. Since ion diffusion and lysis are 294 
passive processes, cell metabolism is not required for AmB to kill cells. Consistent with this mechanism, 295 
AmB killed both growing and non-growing yeast cells (Figure 3). However, although AmB killed cells in 296 
non-proliferating, low-density yeast populations, AmB-tolerant subpopulations were observed in 297 
stationary state planktonic and biofilm populations (Figure 5). 298 
Azole drugs are fungistatic against C. albicans, but less active against other Candida species, which show 299 
a clear increase in cell density after azole treatment
56, 57
. The poor efficacy of the azole drug VOR against 300 
S. cerevisiae cells within the first 7 hours of exposure (Figure 3a) might be because S. cerevisiae and the 301 
closely related C. glabrata share a mechanism that makes them intrinsically resistant to azoles. 302 
 303 
Bacterial cells grown as biofilms or grown to stationary state as planktonic cells have similar drug-304 
tolerance phenotypes
23, 24, 58, 59
; we have in the present study extended this phenotypic similarity to yeast 305 
cells (Figure 5). Our results indicated that the biofilm mode of growth itself does not result in antifungal 306 
tolerance. Rather, the lack of cell division and the physiological state of stationary phase cells is 307 
responsible for the drug-tolerant phenotype. 308 
A combination of factors is probably responsible for the multidrug tolerance of cells in biofilms. 309 
However, as long as biofilm populations contain non-proliferating cells, some of the most commonly 310 
used antimicrobials will have reduced efficacy. Biofilm tolerance to drugs is conditional and depends on 311 
the mode of action of the tested drugs, as well as cell physiology and environment
60
. We showed that 312 
standard laboratory yeast biofilm models and methods can determine cell culture conditions under which 313 
antifungal drugs are effective or ineffective. However, our models and methods did not identify biofilm-314 
specific mechanisms of drug tolerance. Our findings imply that biofilm tolerance phenotypes might be 315 
caused by the large number of stationary cells within mature biofilms rather than specific biofilm 316 
mechanisms. Our data therefore suggest that future research on novel drugs and treatments should focus 317 
12 
 
on strategies that are effective against stationary non-growing cells, rather than attempting to develop 318 
specific anti-biofilm treatments. 319 
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FIGURES 464 
 465 
Figure 1. Saccharomyces cerevisiae and Candida glabrata biofilms have similar sensitivity to antifungal 466 
drugs. (a) MIC values of the indicated antifungal agents against S. cerevisiae. (b) Antifungal drug activity 467 
against 48-hour biofilms was visualized by confocal laser scanning microscopy. GFP-tagged S. cerevisiae 468 
was stained with propidium iodide (PI, 1 µM) to mark living (green) and dead (red) cells. C. glabrata was 469 
stained with Syto9 (3 µM) and PI (1 µM) to mark living (green) and dead (red/yellow) cells. Biofilm cells 470 
were treatment was for 24 hours with the indicated antifungal agents. VOR: voriconazole, 5FC: 471 
flucytosine, CAS: caspofungin, and AmB: amphotericin B.  472 
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 473 
Figure 2. Metabolic activity of yeast cells in biofilms decreases with incubation time. S. cerevisiae cells 474 
stained with FUN-1 (10 µM) after incubation for 4 hours and 48 hours. Metabolically active cells produce 475 
red cylindrical intravacuolar structures.  476 
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 477 
Figure 3. Amphotericin B is the only drug tested with activity against growth-arrested cells. (a) Killing 478 
kinetics of exponentially growing planktonic S. cerevisiae cultivated in 2% glucose exposed to 5 times the 479 
minimum inhibitory concentration (MIC) of the indicated antifungal drugs. (b) Killing kinetics of growth-480 
arrested planktonic S. cerevisiae cultivated in carbon-depleted minimal media exposed to 5 times MIC of 481 
the indicated antifungal drugs. VOR: voriconazole, 5FC: flucytosine, CAS: caspofungin, AmB: 482 
amphotericin B. n = 3, error bars show standard deviations.  483 
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 484 
 485 
Figure 4. Antifungal drugs are active against growing biofilms. (a) Quantitation of biofilm cell viability. 486 
Biofilms were grown for 4 hours and viability determined as CFUs. Biofilms were then treated with 10 487 
times the minimum inhibitory concentration (MIC) of the indicated antifungal drug for 24 hours and 488 
CFUs were measured. Shown is log change in CFUs. n = 3, error bars are standard deviations. 489 
Significance was evaluated with Student’s t-test. **P < 0.01. (b) GFP-tagged S. cerevisiae in 4-hour 490 
biofilms stained with 1 µM propidium iodide visualized by confocal microscopy. Biofilm cells were 491 
treatment was for 24 hours with the indicated antifungal agents. VOR: voriconazole, 5FC: flucytosine, 492 
CAS: caspofungin, and AmB: amphotericin B.  493 
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 494 
 495 
Figure 5. Yeast cells grown in biofilms and planktonic cultures have similar drug tolerance. Cultures 496 
were grown for 48 hours and viability was measured as colony-forming units (CFUs). Cells were treated 497 
with 10 times minimum inhibitory concentration (MIC) of the indicated antifungal drug, or left untreated 498 
as a control, and CFUs were measured after 24 hours. Shown is log change in viability. (a) Wild type S. 499 
cerevisiae Σ1278b grown as biofilms on polystyrene surfaces. (b) Wild type grown planktonically in glass 500 
21 
 
flasks. (c) flo11 knockout mutant grown planktonically in glass flasks. VOR: voriconazole, 5FC: 501 
flucytosine, CAS: caspofungin, AmB: amphotericin B. n = 3, error bars show standard deviation. 502 
Statistical significance was evaluated with Student’s t-test. **P < 0.01. 503 
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ABSTRACT 28 
Microbial biofilm formation is associated with decreased treatment success and persistent infections. Yeast 29 
infections are an increasing clinical problem and the ergosterol targeting fungicide amphotericin B is one of 30 
few antifungals with anti-biofilm activity. We show that a sub-population of Saccharomyces cerevisiae 31 
biofilm cells survived amphotericin B treatment. Re-inoculation of the surviving cells produced a similar 32 
proportion of drug tolerant cells, suggesting non-inherited resistance. To identify the molecular and 33 
physiological factors that contribute to the underlying amphotericin B tolerance in yeast biofilms, we 34 
screened a pooled collection of gene deletion mutants grown as biofilm or planktonic cells. Using 35 
multiplexed barcode sequencing (Bar-seq), we found that cells with mutations in genes involved in 36 
proliferation and metabolism were more tolerant to amphotericin B. The overlap between the specific genes 37 
selected for by growth in biofilm or planktonic growth was significant, and network analysis revealed 38 
overlap in the molecular pathways selected by specific modes of growth, suggesting that tolerance 39 
mechanisms are shared between biofilm and planktonic cells. We found that the level of tolerance to 40 
amphotericin B could be enhanced by prolonged starvation and rapamycin treatment. Our study contributes 41 
to the knowledge of the molecular mechanisms underlying biofilm drug tolerance and might lead to 42 
development of novel treatment strategies targeting quiescent cells.    43 
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INTRODUCTION 44 
Advances in medical procedures have increased the use of invasive devices and immunosuppressive 45 
treatment, but at the same time have led to an increase in the number of patients susceptible to fungal 46 
infections [1]. It is believed that microbial biofilm formation is an important process in fungal infections [2]. 47 
The biomaterial of medical implants serves as compatible surfaces for attachment of fungal cells and the use 48 
of invasive devices are a risk factor for fungal biofilm infections [3]. The ability of biofilm cells to survive 49 
treatment with antimicrobial agents is a major challenge in treatment of infections and the molecular 50 
mechanisms that underlie drug tolerance of biofilm cells are not fully understood [4]. 51 
 52 
The majority of microbial cells in nature are thought to live in nutrient limited environments. Starvation for 53 
essential nutrients results in decreased metabolism and reduced cell growth. Decreased growth rate is 54 
correlated with increased stress tolerance [5,6] and stationary phase cells can survive exposure to a wide 55 
range of stress conditions [7]. The stationary state is defined by no net increase in population density [8] and 56 
includes heterogeneous population with phenotypic diverse sub-populations [9]. Even though the stationary 57 
state might be the most common growth state in nature, the knowledge about this phase is limited compared 58 
to our knowledge on exponential growth. Cells within biofilms have many phenotypic similarities with 59 
stationary state planktonic cells including low metabolism, phenotypic heterogeneity, and increased stress 60 
tolerance [10,11]. Few antifungal drug classes are available for treatment of systemic mycoses. The azoles 61 
account for the majority of total antifungal consumption and consequently an increase in non-susceptible 62 
Candida isolates have been reported [12]. Alternatives to the azoles are limited and only echinocandins and 63 
polyenes have in vitro activity against fungal biofilms [11,13,14].  64 
The polyene drug amphotericin B has antifungal activity against a broad spectrum of fungal species making 65 
it the gold standard for treatment of severe mycoses. The drug targets ergosterol in the fungal cell membrane 66 
and form pores that result in rapid cell lysis [15]. The fungicidal properties of amphotericin B make it one of 67 
the few systemic antifungals with activity against growth arrested cells [11]. However, amphotericin B is 68 
unable to eradicate an entire population of biofilm and stationary state planktonic cells [11,16]. Because 69 
amphotericin B is the last in line treatment option, failure of amphotericin B treatment can have fatal 70 
consequences. Still, resistance to amphotericin B is rarely reported in the clinic and knowledge about the 71 
mechanisms is mainly limited to alterations of the target molecule or cell wall [15]. 72 
 73 
The genetically tractable Saccharomyces cerevisiae is closely related to the pathogenic yeast Candida 74 
glabrata [17] and is used as an experimental model for fungal biofilm studies [11,18,19].  A powerful 75 
molecular genetic tool available in S. cerevisiae is comprehensive barcoded gene-deletion strain collections 76 
which enable systematic studies of protein function and genotype to phenotype correlations [20]. The unique 77 
barcode tags of each mutant in combination with the advances of next generation sequencing create a 78 
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platform to perform cost efficient, high throughput, multiplexed screens of pooled mutants [21]. In this 79 
study, we used a gene deletion collection in a biofilm competent strain [22] to screen for mutants with 80 
increased tolerance to amphotericin B treatment when grown to starvation as planktonic or biofilm cells. We 81 
developed our experimental setup to be compatible with the suggested guidelines for design and analysis of 82 
Bar-seq experiments [23]. The biofilm and planktonic populations were treated with amphotericin B and 83 
samples were subsequently outgrown to enrich for viable cells. Genomic DNA was purified from the 84 
samples and the molecular barcodes that uniquely identifies each mutant were amplified and sequenced.  85 
Our results show that the level of drug tolerance could be induced and enhanced by prolonged starvation, 86 
exposure to rapamycin, or introduction of specific errors in metabolism and proliferation processes. A 87 
significant number of mutants were found to be tolerant in both biofilms and planktonic cultures. The gene 88 
products of the mutated genes uniquely identified in either mode of growth are involved in the same 89 
processes of the cell despite mode of growth, suggesting that identical mechanisms are responsible for drug 90 
survival in planktonic and biofilm populations.  91 
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MATERIALS AND METHODS 92 
Strains 93 
Saccharomyces cerevisiae Σ1278b YS-11 (MATa can1Δ::STE2p-spHIS5 lyp1Δ::STE3p-LEU2 his3::HisG 94 
leu2Δ ura3Δ)  was used as reference wild type strain (Boone Lab, University of Toronto). The S. cerevisiae 95 
Σ1278b haploid gene-deletion collection (MATa can1Δ::STE2p-spHIS5 lyp1Δ::STE3p-LEU2 his3::HisG 96 
leu2Δ ura3Δ) [22] was transferred from 96-well glycerol stock plates to YPD agar and incubated at 30°C for 97 
three days. Colonies were subsequently pooled in YPD medium and incubated overnight in glass flasks with 98 
agitation at 30°C. Samples were spun down and dissolved in 5 ml YPD with 20% glycerol and frozen at        99 
-80°C.  100 
 101 
Media and growth conditions 102 
The Bar-seq experiment and all biofilm experiments were performed in minimal medium with 6.7 g/L Yeast 103 
Nitrogen Base without amino acids (BD Difco) and 2.0 g/L glucose supplemented with amino acids (Table 104 
S1). Yeast extract peptone dextrose (YPD) [24] medium was used for cultivation of planktonic cells except 105 
in the Bar-seq screen. All experiments were performed at 30°C.  106 
 107 
Minimal inhibitory concentration 108 
Minimal inhibitory concentrations (MIC) were determined as previously described [25] with modifications. 109 
In short, a two-fold dilution series of amphotericin B was prepared in fresh medium and distributed into 96-110 
well microtiter plate. Visibly turbid overnight cultures were diluted to OD600 0.1 in fresh medium and 111 
transferred to microtiter plates containing amphotericin B. Plates were incubated with agitation (60 rpm) at 112 
30°C for 24 h and biomass was measured with a microplate spectrophotometer (BioTek PowerWave 340). 113 
Growth inhibition of ≥ 90% was determined as MIC as recommended by EUCAST [25]. MIC values were 114 
determined in YPD medium and minimal medium with 2% glucose.  115 
 116 
Barcode sequencing 117 
Cultivation 118 
The pooled mutant collection was inoculated in quadruplicate to 700 ml minimal medium at density 5.0 ± 0.2 119 
log10 CFU/ml. After 5 hours agitated incubation at 30°C, 50 ml samples were distributed to CELLSTAR Cell 120 
Culture Dishes (Cat. No. 639 160, Greiner Bio) and sealed with parafilm to avoid evaporation for biofilm 121 
growth, or glass flasks for planktonic growth. The cells were grown for 96 hours followed by 12 hours 122 
treatment with amphotericin B (see below). 123 
 124 
Drug treatment 125 
Amphotericin B (A2411, Sigma) was dissolved in DMSO in 5 mg/ml stock solution and kept at -20°C. After 126 
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96 hours cultivation of biofilm and planktonic cells, amphotericin B was added to a final concentration of 10 127 
µg/ml, corresponding to ten times the MIC in minimal medium, directly to planktonic growing cells in the 128 
glass flasks. For biofilm growing cells, medium with non-attached cells was removed and centrifuged (10 129 
minutes at 4500 G) and amphotericin B was added to the spent medium to a final concentration of 10 µg/ml 130 
before reintroduction to biofilm cells. Drug treated samples were shielded with alufoil to protect 131 
amphotericin B from light and incubated for 12 hours.     132 
 133 
DNA extraction from viable mutants 134 
Cells were harvested from biofilm growing cells by removing media with non-adhering cells, washing the 135 
biofilm-forming population in saline to remove excess planktonic and loosely adherent cells. Finally, biofilm 136 
cells were dissolved in saline and scraped off the surface with a Drigalski spatula and homogenized. 137 
Planktonic growing cells from glass flasks were centrifuged for 10 minutes at 4500 G and the cell pellets 138 
were washed once in saline. Cell pellets were dissolved in saline after an additional centrifugation step the. 139 
One ml of harvested cell culture was transferred to 25 ml YPD and outgrown at 30°C with agitation to enrich 140 
for viable mutants. Genomic DNA was extracted with the Wizard Genomic DNA Purification kit (A1125, 141 
Promega). 142 
 143 
Library preparation 144 
Amplification of molecular barcodes from genomic DNA and incorporation of the Illumina P5 sequence was 145 
performed in a two-step PCR protocol as previously described with a few modifications [23]. In short, 146 
UPTAGs and DNTAGs were amplified in the first PCR reaction with unique index primers (Table S2) and 147 
purified PCR concentrations were estimated from gel band intensities. UPTAGs and DNTAGs were mixed 148 
in separate pools with 10 ng for each library. In a second PCR step, the Illumina P5 sequence was 149 
incorporated to the UPTAGs and DNTAGs in two separate PCR reactions. The two PCR products were 150 
subsequently combined in equimolar amounts and diluted to a 2 nM final concentration. The library was 151 
sequenced on a single lane of an Illumina HiSeq 2000.  152 
 153 
Data analysis 154 
Sequence reads were matched to a library of known barcode sequences allowing single mismatch 155 
annotations [21]. The HO knockout strain was present multiple times in the 96-well stock plates that the 156 
deletion collection was pooled from. This strain accounted for 30% of total sequence reads and was 157 
consequently removed from the data set. UPTAG and DNTAG reads (Figure S1) within each biological 158 
replicate were summed and normalized to total reads per sample. Low abundant mutants were filtered if the 159 
mutant was present less than a 100 counts per million in less than four samples leaving a total of 2051 160 
mutants for further data analysis. Because the variance of biological replicates was higher than the mean 161 
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(Figure S2), the data set followed an overdispersed Poisson distribution, and the edgeR package (version 162 
3.2.4) was used for differential abundance analysis as previously described [23]. A false discovery rate 163 
(FDR) < 0.05 was considered significant.  164 
 165 
Gene ontology 166 
Genes found to be significantly overrepresented after amphotericin B treatment were manually assigned a 167 
biological function and grouped based on gene ontology as annotated by the Saccharomyces Genome 168 
Database (SGD). All gene ontology groups were verified by GO Term Finder from SGD. 169 
 170 
Protein interaction network 171 
Protein interaction network was made with the MiMI plugin (3.1) [26] to cytopscape (2.8.3) [27]. The 172 
network contain interactions between proteins from gene products of deleted genes that resulted in 173 
significant increased survival to amphotericin B. The network include proteins that interacts with at least one 174 
other protein found in the Bar-seq screen.  175 
 176 
Phenotypic characterization of drug-tolerant biofilm sub-population 177 
Yeast cultures with cell density OD600 0.1 were distributed to the wells of a microtiter plate with a 178 
polystyrene surface. After two days static incubation, medium with planktonic and loosely adherent cells 179 
were removed and centrifuged (2 min at 10000 g). Biofilm cells were challenged for 24 hours with the 180 
indicated concentrations of amphotericin B added to the supernatant of the spent medium. Biofilm cells were 181 
washed twice in saline, re-dissolved and serial diluted in saline before plating on YPD agar. Inheritance of 182 
drug tolerant phenotype was investigated by re-dissolving amphotericin B (ten times MIC) exposed biofilm 183 
cells in fresh medium and transfers them to a new microtiter plate. After two days incubation, the biofilm 184 
population was exposed to amphotericin B (ten times MIC) in a total of three cycles identical to that just 185 
described. 186 
 187 
Confocal microscopy 188 
Visibly turbid cultures were diluted to OD600 0.1 and transferred to biofilm chambers (Technical University 189 
of Denmark) with a polyvinyl chloride (PVC) coverslip surface (Rinzl, Electron Microscopy Sciences). After 190 
96 hours static incubation at 30°C, medium was removed from biofilm chambers and centrifuged, and 191 
antifungal drug was added to the supernatants at 10 times the MIC. Spent medium with drug was introduced 192 
to the biofilm cultures followed by 12 hours incubation at 30°C. Rapamycin inhibition of biofilm cells was 193 
performed by incubation of fresh cultures with and without 1 µg/ml rapamycin for four hours followed by 3 194 
hours amphotericin B treatment (10 times MIC). Staining for 15 minutes with 5 µM Syto9 (Invitrogen) was 195 
used to visualize live cells and 20 µM propidium iodide (Sigma-Aldrich) was used to stain dead cells. 196 
8 
 
Confocal laser scanning microscopy (CLSM) was performed with a Zeiss LSM710 microscope equipped 197 
with excitation lasers at 488 nm and 514 nm. Imaging used an EC Plan-Neofluar 40x/1.30 Oil lens. 198 
 199 
Growth conditions for planktonic populations  200 
Exponential growing yeast cells were dissolved in fresh pre-heated YPD medium to OD600 0.1 in glass 201 
flasks. Half of the cultures were exposed to 1 µg/ml rapamycin (R0395, Sigma) from a 1000 µg/ml stock 202 
solution in DMSO, while the other half were kept untreated. The cultures were incubated at 30°C with 203 
agitation (200 rpm). 204 
 205 
Growth curves 206 
Samples were extracted for OD600 measurements before addition of rapamycin (t0) and every hour post 207 
rapamycin treatment.  208 
 209 
Drug susceptibility 210 
Exponential growing rapamycin-untreated cells were exposed to five times the MIC amphotericin B, while 211 
the other half of the cells were pre-exposed to rapamycin for four hours before treatment with five times 212 
MIC of amphotericin B. CFUs were determined before and every hour post amphotericin B treatment for 213 
killing kinetics, and only after two hours in the mutant viability assay.  214 
Starvation induced tolerance was investigated by diluting an exponential growing population to OD600 0.01 215 
in glass flasks and incubating it for 24 hours or five days with agitation, followed by treatment with 50 times 216 
MIC of amphotericin B for three hours. Viable cells were determined by CFUs.  217 
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RESULTS 218 
 219 
Surviving cells are phenotypic variants of wild type 220 
Amphotericin B has been reported to kill the majority of yeasts cells in a biofilm population, but 221 
reproducibly fails to eradicate a sub-population of cells that remain viable after treatment with 10 times the 222 
MIC [11].  223 
To determine the correlation between drug concentration and cell density of the amphotericin B tolerant sub-224 
population, biofilm cells were exposed to high concentrations of amphotericin B for 24 hours. Treatment 225 
with 10 µg/ml (10 times the MIC in minimal medium) resulted in survival of 5.0 ± 0.4 log10 CFU/ml (Figure 226 
1A). Exposure to 50 µg/ml (50 times the MIC) decreased the population size to 4.9 ± 0.2 log10 CFU/ml and 227 
treatment with 100 µg/ml (100 times the MIC) resulted in 4.1 ± 0.4 viable log10 CFU/ml. No statistical 228 
significance was observed between treatment doses (P > 0.05, one-way ANOVA), showing that survival is 229 
not drug concentration-dependent.  230 
We next investigated the inheritance of the amphotericin B tolerance phenotype. Yeast biofilms were 231 
exposed to 10 µg/ml of amphotericin B for 24 hours after which the surviving biofilm population was re-232 
inoculated to form a new biofilm. The new biofilm was treated again and this procedure was repeated in a 233 
total of three inoculation and treatment cycles (Figure 1B). If the survival mechanism was mediated by 234 
resistant mutations, a significant increase in surviving cells would have been expected to occur after each 235 
treatment cycle. After the first cycle, 4.9 ± 0.2 log10 CFU/ml survived the amphotericin B treatment. The 236 
biofilm population produced by the surviving cells showed similar tolerance to amphotericin B as its 237 
progenitor with 5.3 ± 0.3 log10 CFU/ml. An additional cycle repeating this procedure showed that 4.5 ± 1.9 238 
log10 CFU/ml survived exposure to amphotericin B. There was no significant difference between the size of 239 
the amphotericin B tolerant population (P = 0.7314, one-way ANOVA), suggesting that tolerance was not 240 
heritable.  241 
 242 
Screening for Amphotericin B tolerant mutants using multiplexed barcode sequencing  243 
Multiplexed barcode sequencing [23] was used to identify genes and processes that contribute to the 244 
generation of non-heritable tolerance of amphotericin B in nutrient starved planktonic and biofilm 245 
populations. The barcoded mutant collection was pooled and four biological replicates were inoculated to 246 
individual glass flasks followed by distribution to plastic surfaces for biofilm growth and to new glass flasks 247 
for planktonic growth (Figure 2A). After four days incubation, four biological replicates were treated with 248 
amphotericin B and four were kept untreated for both biofilm and planktonic populations. After 12 hours, 249 
cell samples for each biological replicate, treated and untreated, were extracted and outgrown to enrich for 250 
DNA from the surviving mutants prior to molecular barcodes sequencing.   251 
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We used multidimensional scaling (MDS) to investigate the concordance between biological replicates. We 252 
found that all biological replicates for untreated control samples grouped together and that both untreated 253 
control samples for biofilm and planktonic growth were found in the same cluster (Figure 2B). This shows 254 
high similarity in abundance of mutants between biofilm and planktonically grown populations. For the 255 
amphotericin B treated samples (triangles), three out of four biological replicates grouped together for both 256 
biofilm and planktonic grown cells. This indicates diverse selection of tolerant mutants upon amphotericin B 257 
treatment. 258 
 259 
Mutant abundance after amphotericin B treatment 260 
The pooled mutant collection grown as biofilm for four days reached a cell density of 6.8 ± 0.05 log10 261 
CFU/ml (Figure 3A). After treatment with amphotericin B for 12 hours, the viable population decreased to 262 
4.1 ± 0.5 log10 CFU/ml. Planktonic growth of the pooled mutant library resulted in a cell density of 7.0 ± 263 
0.05 log10 CFU/ml after four days incubation. Amphotericin B treatment for 12 hours resulted in survival of 264 
5.3 ± 0.2 log10 CFU/ml. The tolerant population was more than 10 times larger after planktonic growth 265 
compared to biofilm growth, indicating higher tolerance in planktonic cells. The higher standard deviation 266 
for drug treated samples compared to untreated further support the observation from the MDS plot (Figure 267 
2B) that amphotericin B treatment increase heterogeneity of biological replicates. 268 
We found 248 mutants to be significantly (FDR < 0.05) more abundant in biofilm cells after drug treatment 269 
(Table S3) and 179 were found for planktonic cells (Table S4). We found that 184 mutants were uniquely 270 
identified for biofilm and 115 were unique for planktonic cells (Figure 3B). A total of 64 mutants were found 271 
to be shared between the two modes of growth (Table S5), which was found to be significant (P < 0.0001, 272 
two-tailed Fischer’s exact test) showing that the overlap was larger than expected by chance. This result 273 
indicates that S. cerevisiae has a large group of genes that confer amphotericin B tolerance in both biofilm 274 
and planktonic cultures.  275 
 276 
Nine mutants were found to be hyper-susceptible to amphotericin B when grown as biofilm and two mutants 277 
were hyper-susceptible when cultivated as planktonic cells (Table S6). Three of the amphotericin B hyper-278 
susceptible mutants identified for biofilm growth have deletions in genes with unknown function (Tda11, 279 
YEL057C, and YML003W). Additionally, Sas2 is involved in histone acetylation, Sim1 in cell wall 280 
organization, Gde1 in Glycerophosphocholine catabolism, and Dug3 in glutathione catabolism. The hyper-281 
susceptible mutants identified in planktonic cultivated cells have gene deletions in the plasma membrane 282 
transporter Yor1 and the biotin synthesis gene Bio5. Because these mutants are unrelated and are not 283 
involved in overlapping biological processes, we chose to focus on mutants that increase survival in the rest 284 
of this study. 285 
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Deletion of protein synthesis and cell division cycle genes increase amphotericin B tolerance 286 
We found 6% in biofilm and 5% in planktonic of the genes resulting in increased amphotericin B survival to 287 
be involved in lipid metabolism such as the ergosterol biosynthesis genes Ncp1, Cyb5 and Erg5 (Table 1, 288 
Table S7 and Table S8). The deletion of these genes likely results in structural modification of lipids leading 289 
to lowered affinity of ergosterol to amphotericin B [28]. Structural modification of ergosterol is a well 290 
described resistance mechanism against amphotericin B [15] and the identification of such mutants serves as 291 
positive validation of the Bar-seq screen.   292 
The majority of identified mutants are affected in metabolic processes of the cell. Among them we found a 293 
large group of mutants with knockouts in genes involved in transcription and translation processes of the 294 
cell, including regulators of RNA polymerase II and ribosomal proteins (8 for biofilm cells and 11 for 295 
planktonic cells). Additionally, mutants deleted in metabolism of carbohydrates and small molecules such as 296 
carboxylic acids and amino acids showed increased amphotericin B tolerance.  297 
We also observed a group of mutants involved in transport processes in the cell to increase amphotericin B 298 
survival. One-third of this group was involved in protein transport (34% in biofilm and 37% in planktonic), 299 
one-fourth in ion transport (24% in biofilm and 30% in planktonic), and carboxylic transport accounted for 300 
15% in biofilm and 17% in planktonic cells.    301 
Finally, we found that mutations in cell cycle processes increased amphotericin B tolerance. From this gene 302 
ontology, 41% for biofilm and 40% for planktonic were involved in cell cycle phase transition, while one-303 
fifth was involved in G2/M transition of the mitotic cell cycle (18% for biofilm and 20% for planktonic), and 304 
one-fifth was involved in cytokinesis (23% for biofilm and 20% for planktonic).  305 
These observations show that cells with increased tolerance may be impaired in central metabolic and cell 306 
proliferation processes.  307 
 308 
Mutants have increased initial proportion of amphotericin B tolerant cells 309 
To confirm the involvement of individual genes on drug tolerance we investigated the susceptibility of 310 
individually cultured mutants to amphotericin B treatment. We chose to focus on the shared genes between 311 
biofilm and planktonic cultivated cells, because this group was found to be significant and holds great 312 
therapeutic potential. We included ssn3 (nucleic acid metabolism), gin4 (cell cycle process), slm1 (signal 313 
transduction), erg5 (lipid metabolic process) and sac1 (lipid metabolic process).  314 
MIC determinations showed that only erg5 had a reduction in amphotericin B susceptibility, while the 315 
remaining tested mutants all had MIC values similar to the wild type (Figure 4A). Because the MIC assay 316 
measures the ability to grow in the presence of an antifungal agent, these results suggested that the high level 317 
of amphotericin B tolerance of the mutants could be attributed to a non-growing cell state.  318 
To investigate the initial population size of amphotericin B tolerant cells in the mutants, we treated 319 
exponential growing cells for two hours with amphotericin B and determined CFUs before and after 320 
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amphotericin B treatment. Treatment of exponential growing wild type cells with amphotericin B resulted in 321 
survival of 0.5% of the population (Figure 4B). Treatment of slm1 resulted in survival of 0.3%, which was 322 
found to be significantly lower compared to wild type (P < 0.05, Student’s t-test). Treatment of the mutants 323 
gin4, erg5, ssn3, and sac1 all resulted in a significant increase in surviving populations (P < 0.05, Student’s 324 
t-test). These results show that for gin4, erg5, ssn3, and sac1, significantly more cells are in a tolerant state 325 
during exponential growth compared to the wild type.  326 
 327 
Inhibition of TORC1 increases amphotericin B tolerant population 328 
The TOR pathway is responsible for regulation of growth and controlling metabolic processes in yeast cells 329 
in response to nutrient availability [29]. Inhibition of this pathway leads to growth arrest of cells in a 330 
quiescent G0 state that can be induced by nutrient starvation or treatment with rapamycin [30]. Although tor1 331 
and tor2 were not part of the screen, we found that deletion of members of the EGO complex (gtr1, gtr2, 332 
meh1, and slm4) that is required for exit of TOR-inhibited growth arrest [31] increased amphotericin B 333 
survival in our Bar-seq screen. Moreover, 20% of the shared genes between biofilm and planktonic 334 
cultivated cells that resulted in increased amphotericin B tolerance when deleted have previously been shown 335 
to have changed susceptibility to rapamycin, 81% of them being hyper-susceptible to rapamycin (Table S9) 336 
[32]. This indicate that the TOR inhibited response is induced with higher sensitivity in these mutants and 337 
shows that biofilm and planktonic cells share this pathway in tolerance to amphotericin B. 338 
Treatment of the wild type with 1 µg/ml rapamycin resulted in growth arrest of exponential growing cells 339 
(Figure 5A). This allowed us to compare amphotericin B tolerance of exponential growing cells and TORC1-340 
inhibited growth arrested cells. Rapid killing kinetics was observed after amphotericin B treatment of 341 
exponential growing cells resulting in killing of > 99% of the cells after three hours. Amphotericin B 342 
treatment of rapamycin-induced growth arrest resulted in slow killing with a ~500-fold increased 343 
amphotericin B tolerant population compared to exponential growing cells (Figure 5B). Rapamycin 344 
treatment was also found to be effective against growing yeast biofilm cells. Yeast cells were cultivated as 345 
biofilm for four hours with and without rapamycin. Rapamycin treated cells were growth inhibited and had a 346 
lower population density compared to untreated cells. Amphotericin B treatment of rapamycin exposed cells 347 
increased the ratio of surviving cells compared to untreated cells, showing that TORC1 inhibition result in 348 
increased survival of biofilm cells to amphotericin B treatment (Figure 5C). 349 
Treatment with rapamycin inhibited the growth of yeast cells, but this might not fully represent the nature of 350 
nutrient starved cells. To investigate the effect on amphotericin B tolerance of naturally starved cells, a 351 
population of yeast cells cultured for one day (post diauxic shift) and five days (stationary phase) were 352 
exposed to 100 µg/ml amphotericin B for three hours (Figure 5D). Our results showed that prolonged 353 
starvation significantly (P < 0.005, Student’s t-test) increased the amphotericin B tolerant sub-population. 354 
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In Figure 4B we observed that slm1 did not contain a larger proportion of amphotericin B tolerant cells 355 
compared to wild type in exponential growth phase. However, incubation for 96 hours in minimal medium 356 
before amphotericin B treatment resulted in a significant higher level of amphotericin B tolerance in slm1 357 
biofilm compared to wild type biofilm cells (P < 0.05, Student’s t-test) (Figure 6B). Similarly, when 358 
exponential growing planktonic cells were pre-exposed for four hours to rapamycin, significantly more slm1 359 
cells were amphotericin B tolerant compared to wild type (P < 0.0001, Student’s t-test) (Figure 6B). These 360 
results indicate that nutrient starvation and TORC1 contribute to amphotericin B tolerance in slm1, while 361 
other additive factors are also responsible for tolerance in gin4, erg5, ssn3, and sac1 (Figure S4). 362 
 363 
Similar interaction networks lead to amphotericin B tolerance in biofilm and planktonic cultures 364 
We created a protein interaction network of the gene products that when deleted uniquely resulted in 365 
amphotericin B tolerance unique for biofilm or planktonic growth to identify the molecular networks 366 
affecting growth specific amphotericin B tolerance. Of the 184 genes identified to increase tolerance in 367 
biofilms, 79 genes encode proteins that interact with at least one other protein found to be unique for either 368 
biofilm or planktonic growth (Figure 7). Only four of them were found to not have at least a third degree 369 
interaction with a protein identified to be unique for planktonic cells. For proteins identified in the planktonic 370 
screen, 52 proteins were found to interact with at least one other protein identified to be growth specific in 371 
the Bar-seq screen. Only two proteins were found to not have at least a third degree interaction with a protein 372 
found to be unique for biofilm cells. We found a substantial overlap in molecular networks affecting 373 
amphotericin B tolerance under both growth conditions. Although the majority of mutants were found to 374 
uniquely increase survival during either biofilm or planktonic mode of growth, the gene products of the 375 
knockouts interact with each other independent of mode of growth, suggesting that they are involved in the 376 
same pathways. Moreover, genes identified in biofilm or planktonic growth could be assigned to the same 377 
biological function gene ontologies (Table 1). We found ~1.5-fold more genes that upon knockout resulted in 378 
increased tolerance to amphotericin B when grown as biofilm compared to planktonic cultivation. This fold 379 
difference recurs in almost all biological function groups and each group account for similar percentages of 380 
the total significant genes (Table 1). These observations strongly imply that even though more gene deletions 381 
were found to uniquely increase amphotericin B survival in biofilm cells compared to planktonic cells, the 382 
genes are involved in the same biological processes.   383 
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DISCUSSION 384 
The molecular mechanisms underlying antimicrobial drug tolerance of biofilm cells are major puzzles in 385 
modern medicine. Attempts to identify biofilm specific mechanisms that can explain multidrug tolerance 386 
have been inconsistent [33]. Research in bacteria have shown that nutrient limitation in biofilm and 387 
planktonic cells activate a starvation response that increase antimicrobial tolerance showing that 388 
antimicrobial drug tolerance mechanisms are shared between nutrient starved biofilm and planktonic bacteria 389 
[34-36]. We have recently shown that planktonic and biofilm yeast cells share similar tolerance phenotypes 390 
when grown to starvation [11]. In the present study, we investigated the molecular mechanisms responsible 391 
for tolerance to the fungicidal drug amphotericin B in nutrient starved population of biofilm and planktonic 392 
yeasts. Using multiplexed barcode sequencing [23] of a pooled mutant collection in a biofilm competent 393 
strain [22], we identified genes involved in cell metabolism and proliferation to be involved in tolerance to 394 
this drug regardless of mode of growth.  395 
 396 
The Bar-seq screen identified genes involved in four major cellular processes. Not surprisingly were genes 397 
involved in lipid metabolism identified as affecting amphotericin B tolerance such as the ergosterol synthesis 398 
genes ERG5, NCP1 and CYB5. Deletion of these genes is likely to result in decreased affinity of the drug to 399 
the plasma membrane. In addition to lipid metabolism, the screen identified that deletion of transcriptional 400 
and translational genes increased survival to amphotericin B treatment. Moreover, genes involved in vesicle 401 
mediated transport of proteins and membrane components between the intracellular compartments affected 402 
amphotericin B tolerance and suggest a role for intracellular remodeling or cytoplasmic membrane 403 
maintenance in survival. Furthermore, mutations in genes involved in the mitotic cell cycle indicate that the 404 
tolerant sub-populations could have arrested growth at different cell cycle phases.  405 
We found a total of 363 gene deletions to increase survival for yeast cells grown as biofilms or 406 
planktonically. The large diversity of cellular processes that can affect amphotericin B tolerance is similar to 407 
the wide range of mechanism that can generate antimicrobial persisters in bacteria, which has been 408 
hypothesized to be the result of fluctuating variability in cellular processes [37]. The many different kinds of 409 
errors that can cause phenotypic variability and the different ways to induce persistence suggests that 410 
persistence is not a unique state, but rather a collection of physiological distinct cellular processes that each 411 
are associated with a drug tolerance phenotype [37,38]. Our results indicate that stochastic variations in cell 412 
metabolism and cell cycle processes could be the cause of phenotypic heterogeneous populations with 413 
amphotericin B tolerant subpopulations. We observed that some of the mutants had a higher initial 414 
proportion of amphotericin B tolerant cells compared to wild type, and the MIC values indicate that this 415 
subpopulation could be growth arrested.     416 
Ceased proliferation and increased stress survival in yeast cells can be attributed to a quiescent state of cell 417 
cycle arrest [7]. Quiescence can be induced by exposure to stress, and is well characterized for stationary 418 
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state populations. Stationary phase populations contain both quiescent and non-quiescent cells that can be 419 
distinguished by the ability of quiescent cells to survive for extended periods of starvation and resume 420 
proliferation when the growth conditions become favorable [9,39]. Similar to Candida albicans biofilm [16], 421 
we found that a subpopulation of the starved cells survived amphotericin B treatment and that it was 422 
phenotypic variants of the wild type, rather than resistant mutants that survived (Figure 1). We furthermore 423 
observed that the amphotericin B tolerant subpopulation resumed growth when reinoculated to fresh medium 424 
without drug, showing that viable cells have quiescent cell properties. Recent investigations indicate that 425 
yeast cells can access distinct quiescent states [40] that can be arrested at all cell cycle phases [41]. Therefore 426 
it seems that quiescence is not a pre-programmed state, but rather a result of slow metabolism that result in 427 
growth arrest [40,41]. Production of heterogeneous populations of quiescent cells might result in 428 
subpopulations with different levels of tolerance to amphotericin B caused by specific defects that we 429 
observed in this study (Figure 4B). It is therefore possible that the genes we identified in the Bar-seq screen 430 
are not directly involved in tolerance but rather affect the proportion of cells entering and leaving the 431 
quiescent state. 432 
 433 
We found that the transition from post diauxic shift to stationary phase significantly enhanced amphotericin 434 
B tolerance (Figure 5D). This result indicates that nutrient depletion associated with stationary phase entry 435 
resulted in acquired stress tolerance to amphotericin B. The highly conserved TOR signaling pathway 436 
controls cell growth in response to nutrient availability. Starvation for carbon or nitrogen inhibit TOR and 437 
result in quiescent cell cycle arrest [29]. Treatment with the immunosuppressive drug rapamycin inhibits 438 
TOR complex 1 (TORC1) and induces a quiescent transcriptional program in yeast [30]. We showed that 439 
pre-exposure to rapamycin increased survival to amphotericin B treatment by ~500-fold (Figure 5B), and that 440 
the entire population of slm1 became tolerant to amphotericin B after pre-exposure to rapamycin (Figure 441 
6C). These results show a role of the TOR signaling pathway in amphotericin B tolerance and that this is a 442 
shared mechanism between planktonic and biofilm starved populations. Furthermore, exit of TOR inhibited 443 
quiescence involves members of the EGO protein complex [31]. We found the EGO mutants gtr1, gtr2, 444 
meh1, and slm4 to increase survival of amphotericin B treatment in glucose starved planktonic and biofilm 445 
cells. The mutants identified to increase amphotericin B tolerance in the Bar-seq screen not only suggest that 446 
phenotype diversity that facilitates higher susceptibility to enter a quiescent state, but also to exit this phase 447 
again, are key tolerance mechanisms.  448 
We suggest that amphotericin B tolerance can be achieved by stochasticity in cell metabolism and cell 449 
proliferation processes and that the proportion of tolerant cells can be enhanced by starvation conditions in a 450 
TOR-dependent manner. We identified ras2 in both biofilm and planktonic cells and ras1 grown as biofilm 451 
to increase amphotericin B survival in the Bar-seq screen. It is therefore likely that other nutrient sensing 452 
systems like the Ras/PKA pathway are also involved in generating amphotericin B tolerance. 453 
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We have found that only a sub-population of growth arrested cells are tolerant to amphotericin B and that 454 
this sub-population contain cells with different kinds of defects and different levels of tolerance. What 455 
distinguish tolerant cells from susceptible cells is likely to be alterations specific for the mechanism of action 456 
of amphotericin B. Amphotericin B target membrane ergosterol and form pores that cause rapid cell lysis. 457 
The yeast cell membrane and cell wall are altered in response to starvation to protect the cell from 458 
environmental stresses and ensure survival during prolonged starvation [7]. Since the overall metabolism of 459 
the cell is decreased during quiescence, catabolism of energy storage is required to remain viable. Fatty acid 460 
oxidation is increased in quiescent cells probably for the utilization of fatty acids as energy source during 461 
starvation [9,39,42]. Since fatty acids are precursors for membrane lipids, it is likely that quiescent cells have 462 
physiochemical changed membranes with decreased affinity to amphotericin B either by lipid raft alterations 463 
or structural modifications of ergosterol. From our screen we did indeed observe mutations in lipid 464 
metabolism to be an important factor in amphotericin B tolerance during starvation. 465 
 466 
One important conclusion of this study is that biofilm and planktonic populations have similar amphotericin 467 
B tolerance mechanisms when pre-exposed to the same stress such as nutrient starvation or rapamycin 468 
treatment. This has also been observed in bacteria [34-36] and strongly suggest that the drug tolerance 469 
associated with biofilms is attributed to the nutrient starved conditions they are exposed to in the lab (i.e. 470 
glucose limited medium) [18,43] or in the human host [36]. Antimicrobial tolerance of biofilm cells is a 471 
consequence of environmental conditions rather than biofilm-specific adaptation. We have shown in this 472 
study that planktonic and biofilm yeast cells pre-exposed to identical environmental stresses respond 473 
similarly to antifungal treatment. 474 
 475 
Our study contribute to the current knowledge about antifungal tolerance of biofilm cells and further insight 476 
into quiescent mediated drug tolerance might lead to development of novel treatment strategies that target 477 
quiescent cells. Understanding survival of quiescent cells is not limited to pathogenic microbes as it is also 478 
relevant in treatment of dormant cancer cells [44].  479 
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TABLES 577 
 578 
Table 1. GO annotations from tolerant mutants identified in the Bar-seq screen.  579 
 580 
GO Biological function Biofilm (%) Planktonic (%) 
6810 Transport 42 (17) 30 (17) 
90304 Nucleic acid metabolic process 28 (11) 33 (18) 
22402 Cell cycle process 22 (9) 10 (6) 
19538 Protein metabolic process 18 (7) 10 (6) 
6629 Lipid metabolic process 15 (6) 9 (5) 
6412 Translation 13 (5) 11 (6) 
44281 Small molecule metabolic process 13 (5) 8 (4) 
7165 Signal transduction 8 (3) 4 (2) 
5975 Carbohydrate metabolic process 6 (2) 6 (3) 
50896 Response to stimulus 5 (2) 6 (3) 
71555 Cell wall organization 2 (1) 7 (4) 
45333 Cellular respiration 3 (1) 3 (2) 
N/A Other 13 (5) 9 (5) 
N/A Unknown 51 (21) 31 (17) 
  581 
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FIGURES 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
Figure 1. Cells that survive amphotericin B treatment are phenotypic variants of wild type . Cultures were 592 
grown for 48 hours as biofilms and viability was measured as colony-forming units (CFUs). Cells were 593 
treated with amphotericin B, or left untreated as a control (-), and CFUs were measured after 24 hours. (A)  594 
Viability of S. cerevisiae wild type cells after treatment with increasing amphotericin B concentrations. (B) 595 
Survival of S. cerevisiae wild type cells after treatment with 10 µg/ml amphotericin B (+). The surviving 596 
population was reinoculated to form a new biofilm that again was exposed to amphotericin B. This was 597 
performed in a total of three inoculation and treatment cycles. n = 3, error bars show standard deviation.   598 
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 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
Figure 2. Experimental design and reproducibility of the mutant screen. (A) A pooled collection of haploid 611 
gene deletion mutants was cultivated as biofilm or planktonic cells in four biological replicates (colored 612 
circles). After four days, half of the biofilm or planktonic populations were treated with 10 µg/ml 613 
amphotericin B for 12 hours (+) or left untreated as control (-). Surviving cells were enriched by outgrowth 614 
in YPD medium before barcode sequencing. (B) Multidimensional scaling plot show the reproducibility of 615 
the four biological replicates. Untreated biofilm cells (blue circles), untreated planktonic cells (red circles), 616 
amphotericin B treated biofilm cells (blue triangles), and amphotericin B treated planktonic cells (red 617 
triangles).   618 
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 619 
Figure 3. Mutant abundance after amphotericin B treatment. The pooled mutant collection cultivated as 620 
biofilm or planktonic cells for four days and treated with amphotericin B for 12 hours. (A) Number of viable 621 
cells measured as CFUs of untreated control (-) and amphotericin B treated cells (+). n = 4, error bars show 622 
standard deviation. (B) Venn diagram showing the overlap of mutants found to be tolerant to amphotericin B 623 
treatment after barcode sequencing. The overlap was significant (P < 0.0001, two-tailed Fischer’s exact test).   624 
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 625 
Figure 4. Amphotericin B tolerant deletion mutants are more susceptible to enter a quiescent state compared 626 
to wild type. (A) Minimal inhibitory concentrations of amphotericin B to selected mutants. Each point 627 
represents an individual experiment. (B) Survival of exponential growing wild type and mutants to two hours 628 
amphotericin B treatment (10 µg/ml). Survival was determined by the percentage difference in CFUs of 629 
amphotericin B treated and untreated cells. n = 3, error bars show standard deviation. Statistical significance 630 
was evaluated with Student’s t-test. ***P < 0.05. Survival was determined by the percentage difference in 631 
CFUs of amphotericin B treated and untreated cells.  n = 3, error bars show standard deviation.   632 
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 633 
 634 
Figure 5. TOR inhibition mediates amphotericin B tolerance. (A) Planktonic cells grown in YPD were 635 
treated with 1 µg/ml rapamycin (+ RAP) or left untreated (- RAP). Samples were extracted every hour and 636 
OD600 was measured for cell density. n = 3, error bars show standard deviation (B) Exponential growing 637 
planktonic cells in YPD were treated with 1 µg/ml rapamycin (+ RAP) for four hours before exposure to 10 638 
µg/ml amphotericin B or only treated with 10 µg/ml amphotericin B (- RAP). CFUs were determined every 639 
hour. n = 3, error bars show standard deviation. (C) Amphotericin B activity against four hour biofilm after 640 
pre-exposure to 1 µg/ml rapamycin (+ RAP) or no rapamycin pre-exposure (- RAP). (D) Survival of 100 641 
µg/ml amphotericin B treatment for three hours of planktonic cells incubated for one or five days. n = 3, 642 
error bars show standard deviation. Statistical significance was evaluated with Student’s t-test. **P < 0.005.  643 
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 644 
Figure 6. Starvation and rapamycin enhance amphotericin B survival. Wild type and slm1 were cultivated 645 
individually as biofilms for four days followed by 12 hours treatment with amphotericin B or left untreated. 646 
(A) Visualization of surviving (green) and dead (red/yellow) cells after LIVE/DEAD staining and confocal 647 
laser scanning microscopy. (B) Quantification of viable cells after amphotericin B treatment. Shown is log 648 
change in viability between treated and untreated cells. n = 3, error bars show standard deviation. Statistical 649 
significance was evaluated with Student’s t-test. ***P < 0.05. (C) Planktonic cells were pre-exposed to 1 650 
µg/ml rapamycin for four hours before two hours amphotericin B treatment (10 µg/ml). Survival was 651 
determined by the percentage difference in CFUs of amphotericin B treated and untreated cells. n = 3, error 652 
bars show standard deviation. Statistical significance was evaluated with Student’s t-test. *P < 0.0001.  653 
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 654 
Figure 7. Similar interaction networks lead to amphotericin B tolerance in biofilm and planktonic cultures. 655 
Protein interaction network of gene products from deleted genes found to uniquely confer tolerance to either 656 
biofilm (blue) or planktonic (red) cells. The network only includes proteins that interact with at least one 657 
other protein found in the Bar-seq screen. Circular symbols represents a direct interaction between two 658 
protein found to be unique for the opposite mode of growth. Diamond symbols in the periphery of the 659 
circular network represent protein with a second or third degree interaction with a protein found to be unique 660 
to the opposite mode of growth. Diamond symbols not attached to the circular network only interact with a 661 
protein found to be unique to the same mode of growth.   662 
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SUPPORTING INFORMATION 663 
 664 
Table S1. Amino acid concentrations used in minimal medium 665 
  
   Supplement Medium 
concentration (mg/l) 
Supplement Medium 
concentration (mg/l) 
    
L-Adenine 35 L-Leucine 180 
L-Alanine 120 L-Lysine 180 
L-Arginine 120 L-Methionine 75 
L-Aspargine 120 L-Phenylalanine 75 
L-Aspartic acid 120 L-Proline 120 
L-Cysteine 180 L-Serine 120 
L-Glutamic acid 180 L-Threonine 150 
L-Glutamine 120 L-Tryptophan 120 
Glycine 120 L-Tyrosine 45 
L-Histidine 120 L-Valine 180 
L-Isoleucine 180 Uracil 120 
 666 
  667 
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Table S2. Primers used for barcode sequencing [23] 668 
Primer Name Primer Sequence 
Illumina UPTAG Index 1 ACG CTC TTC CGA TCT ATACC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 1 ACG CTC TTC CGA TCT ATACC GTG TCG GTC TCG TAG 
Illumina UPTAG Index 19 ACG CTC TTC CGA TCT GGAAC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 19 ACG CTC TTC CGA TCT GGAAC GTG TCG GTC TCG TAG 
Illumina UPTAG Index 20 ACG CTC TTC CGA TCT CTCAG GTC CAC GAG GTC TCT 
Illumina DNTAG Index 20 ACG CTC TTC CGA TCT CTCAG GTG TCG GTC TCG TAG 
Illumina UPTAG Index 21 ACG CTC TTC CGA TCT ACTGG GTC CAC GAG GTC TCT 
Illumina DNTAG Index 21 ACG CTC TTC CGA TCT ACTGG GTG TCG GTC TCG TAG 
Illumina UPTAG Index 22 ACG CTC TTC CGA TCT TACAT GTC CAC GAG GTC TCT 
Illumina DNTAG Index 22 ACG CTC TTC CGA TCT TACAT GTG TCG GTC TCG TAG 
Illumina UPTAG Index 23 ACG CTC TTC CGA TCT GGCAT GTC CAC GAG GTC TCT 
Illumina DNTAG Index 23 ACG CTC TTC CGA TCT GGCAT GTG TCG GTC TCG TAG 
Illumina UPTAG Index 24 ACG CTC TTC CGA TCT CAGTT GTC CAC GAG GTC TCT 
Illumina DNTAG Index 24 ACG CTC TTC CGA TCT CAGTT GTG TCG GTC TCG TAG 
Illumina UPTAG Index 25 ACG CTC TTC CGA TCT ATACC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 25 ACG CTC TTC CGA TCT ACCAG GTG TCG GTC TCG TAG 
Illumina UPTAG Index 26 ACG CTC TTC CGA TCT TTAGC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 26 ACG CTC TTC CGA TCT TTAGC GTG TCG GTC TCG TAG 
Illumina UPTAG Index 27 ACG CTC TTC CGA TCT GCCAC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 27 ACG CTC TTC CGA TCT GCCAC GTG TCG GTC TCG TAG 
Illumina UPTAG Index 28 ACG CTC TTC CGA TCT CGACC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 28 ACG CTC TTC CGA TCT CGACC GTG TCG GTC TCG TAG 
Illumina UPTAG Index 70 ACG CTC TTC CGA TCT TGGTG GTC CAC GAG GTC TCT 
Illumina DNTAG Index 70 ACG CTC TTC CGA TCT TGGTG GTG TCG GTC TCG TAG 
Illumina UPTAG Index 71 ACG CTC TTC CGA TCT GTCCT GTC CAC GAG GTC TCT 
Illumina DNTAG Index 71 ACG CTC TTC CGA TCT GTCCT GTG TCG GTC TCG TAG 
Illumina UPTAG Index 72 ACG CTC TTC CGA TCT CCTTA GTC CAC GAG GTC TCT 
Illumina DNTAG Index 72 ACG CTC TTC CGA TCT CCTTA GTG TCG GTC TCG TAG 
Illumina UPTAG Index 95 ACG CTC TTC CGA TCT GCATA GTC CAC GAG GTC TCT 
Illumina DNTAG Index 95 ACG CTC TTC CGA TCT GCATA GTG TCG GTC TCG TAG 
Illumina UPTAG Index 96 ACG CTC TTC CGA TCT CCGTC GTC CAC GAG GTC TCT 
Illumina DNTAG Index 96 ACG CTC TTC CGA TCT CCGTC GTG TCG GTC TCG TAG 
Illumina UPkanMX CAA GCA GAA GAC GGC ATA CGA GAT GTC GAC CTG CAG CGT ACG 
IlluminaDNkanMX CAA GCA GAA GAC GGC ATA CGA GAT ACG AGC TCG AAT TCA TCG 
Illumina P5 A ATG ATA CGG CGA CCA CCG AGA TCT ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT 
 669 
  670 
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Table S3. Fold change in mutant abundance before and after amphotericin B treatment when cells were 671 
grown as biofilms. 672 
Available from: https://dl.dropboxusercontent.com/u/55799248/TableS3.xlsx 673 
 674 
Table S4. Fold change in mutant abundance before and after amphotericin B treatment when cells were 675 
grown planktonically. 676 
Available from: https://dl.dropboxusercontent.com/u/55799248/TableS4.xlsx 677 
 678 
Table S5. List of mutants that confer amphotericin B tolerance in both biofilm and planktonic populations. 679 
Available from: https://dl.dropboxusercontent.com/u/55799248/TableS5.xlsx 680 
 681 
Table S6. Hyper-susceptible mutants to amphotericin B identified in the Bar-seq experiments 682 
Growth ORF/gene n (%) 
Biofilm YHR159W/TDA11 YMR127C/SAS2 YEL057C YIL123W/SIM1 
YNL191W/DUG3 YPL110C/GDE1 YML003W YDR440W/DOT1 
YGL220W/FRA2 
9 (4) 
Planktonic YGR281W/YOR1 YNR056C/BIO5 2 (1) 
 683 
 684 
Table S7. GO term annotations of amphotericin B tolerant mutants grown as biofilms. 685 
Available from: https://dl.dropboxusercontent.com/u/55799248/TableS7.xlsx 686 
 687 
Table S8. GO term annotations of amphotericin B tolerant mutants grown planktonically. 688 
Available from: https://dl.dropboxusercontent.com/u/55799248/TableS8.xlsx  689 
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Table S9. Rapamycin sensitivity. “-“ denotes hyper-sensitivity to rapamycin, “+” denotes resistance to 690 
rapamycin. Data from [32]. “x” denotes if a mutant with changed rapamycin sensitivity was observed to 691 
result in amphotericin B tolerance. 692 
ORF Name Gene name RapamycinS Both Biofilm Planktonic 
YNL111C CYB5 - x 
  
YDR069C DOA4 - x 
  
YGL043W DST1 - x 
  
YMR015C ERG5 - x 
  
YDR507C GIN4 + x   
YML121W GTR1 - x 
  
YGR163W GTR2 - x 
  
YBR077C NIR1 - x 
  
YJL168C SET2 - x 
  
YPL042C SSN3 + x   
YOL018C TLG2 - x 
  
YML001W YPT7 - x 
  
YKR007W MEH1 - x 
  
YPL150W N/A + x   
YCR094W CDC50 - 
 
x 
 
YOR358W HAP5 +  
x 
 
YBR133C HSL7 - 
 
x 
 
YHR064C PDR13 - 
 
x 
 
YBR284W N/A - 
 
x 
 
YNL297C MON2 - 
  
x 
YMR029C FAR8 - 
  
x 
YNR010W CSE2 - 
  
x 
YGL023C PIB2 - 
  
x 
YGR129W SYF2 +   
x 
YHR034C PIH1 - 
  
x 
YHR045W N/A - 
  
x 
 693 
  694 
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 695 
Figure S1. Sequencing reads of uptag and downtag barcodes  696 
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 697 
Figure S2. Comparison of mean barcode count with associated variance. Grey points are the raw 698 
measurements for each mutant, the red X's are the average variance in each bin, and the blue points are the 699 
estimated variance of each mutant after dispersion shrinkage has been performed.  700 
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 701 
Figure S3. Log10 fold change (logFC) in sequencing reads between drug treated and untreated samples, and 702 
the total abundance of each mutant in the mixed population measured as log10 counts per million (logCPM). 703 
Smear plot showing the correlation between mutant abundancy after amphotericin B treatment and total 704 
number of sequencing counts for biofilm (A) and planktonic (B) grown cells.    705 
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 706 
Figure S4. Inhibition of TOR is and additive effect in amphotericin B survival. Planktonic cells were pre-707 
exposed to 1 µg/ml rapamycin for four hours before two hours amphotericin B treatment (10 µg/ml). 708 
Survival was determined by the percentage difference in CFUs of amphotericin B treated and untreated cells. 709 
n = 3, error bars show standard deviation. Statistical significance was evaluated with Student’s t-test. ***P < 710 
0.05. 711 
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Abstract
The peptidomimetic LTX109 (arginine-tertbutyl tryptophan-arginine-phenylethan) was previously shown to have
antibacterial properties. Here, we investigated the activity of this novel antimicrobial peptidomimetic on the yeast
Saccharomyces cerevisiae. We found that LTX109 was an efficient fungicide that killed all viable cells in an exponentially
growing population as well as a large proportion of cells in biofilm formed on an abiotic surface. LTX109 had similar killing
kinetics to the membrane-permeabilizing fungicide amphotericin B, which led us to investigate the ability of LTX109 to
disrupt plasma membrane integrity. S. cerevisiae cells exposed to a high concentration of LTX109 showed rapid release of
potassium and amino acids, suggesting that LTX109 acted by destabilizing the plasma membrane. This was supported by
the finding that cells were permeable to the fluorescent nucleic acid stain SYTOX Green after a few minutes of LTX109
treatment. We screened a haploid S. cerevisiae gene deletion library for mutants resistant to LTX109 to uncover potential
molecular targets. Eight genes conferred LTX109 resistance when deleted and six were involved in the sphingolipid
biosynthetic pathway (SUR1, SUR2, SKN1, IPT1, FEN1 and ORM2). The involvement of all of these genes in the biosynthetic
pathway for the fungal-specific lipids mannosylinositol phosphorylceramide (MIPC) and mannosyl di-(inositol phosphoryl)
ceramide (M(IP)2C) suggested that these lipids were essential for LTX109 sensitivity. Our observations are consistent with a
model in which LTX109 kills S. cerevisiae by nonspecific destabilization of the plasma membrane through direct or indirect
interaction with the sphingolipids.
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Introduction
Infections caused by pathogenic yeast such as Candida spp. affect
a large number of immunosuppressed patients and are an
increasing medical problem [1,2]. Fungal infections are currently
treated with one of four major classes of antifungals. Azoles target
ergosterol synthesis [3], polyenes bind to ergosterol in the cell
membrane and form pores [4,5], echinocandins inhibit cell wall
synthesis [6], and 5-fluorocytosine interferes with protein and
DNA synthesis [7].
Decreased susceptibility to the most frequently used antifungal,
fluconazole, has recently been reported, and the number of
nonsusceptible C. glabrata isolates from humans is increasing [8,9].
Resistance towards 5-fluorocystosine is also rapidly developing
[10]. Polyenes can be toxic [11] and echinocandins have a narrow
spectrum of activity [12]. An additional complication in the
treatment of nosocomial fungal infections is the frequent formation
by fungi of sessile communities called biofilms in association with
medical implants [13]. Limited nutrient access leads to slow-
growing, antibiotic tolerant cells in biofilms that can serve as a
reservoir for infection [14,15]. Most systemic antifungals are
fungistatic against yeasts, so they are primarily effective against
actively growing cells and have poor activity against cells in
biofilms.
The limited number of antifungal classes and drugs with
fungicidal properties raises the need for novel drugs with activity
against slow-growing and biofilm-forming pathogenic fungi
[16,17]. Antimicrobial peptides (AMPs) and modified forms of
AMPs offer an attractive alternative to conventional antifungal
drugs. AMPs are cationic and amphipathic peptides of 12–50
amino acids that are produced by species in almost every kingdom
and phylum of life [18]. The amphipathic structure of AMPs
suggests that they might have targets that are different from
conventional antifungals [19,20]. The high degradation rate of
many natural AMPs can be circumvented by backbone and side
chain alterations that create structural analogs that mimics natural
peptides [21]. A number of synthesized peptidomimetics have in
vitro antifungal activity, making these compounds attractive
candidates for novel antifungal drugs [22–24].
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We tested the antifungal activity of the short, antibacterial
peptidomimetic LTX109 (arginine-tertbutyl tryptophan-arginine-
phenylethan). LTX109 is based on an Arg-Trp-Arg sequence
found in the AMP bovine lactoferricin and was originally
developed as an antibacterial [25–27].
We used killing kinetics to describe the antimicrobial effect of
LTX109 and investigated its mode of action by measuring
transport of H+, K+, amino acids and a fluorescent dye across the
cell membrane. To uncover potential molecular targets that would
explain the fungicidal activity of LTX109, we screened a
Saccharomyces cerevisiae gene deletion library for mutants resistant
to LTX109. Most mutations that led to LTX109 resistance were
in genes involved in the synthesis of the sphingolipids mannosy-
linositol phosphorylceramide, MIPC, and mannosyl di-(inositol
phosphoryl) ceramide, M(IP)2C. These results indicate that
M(IP)2C and/or MIPC in the plasma membrane are essential
for the action of LTX109.
Materials and Methods
Strains, growth media and antifungal drugs
The S288c S. cerevisiae strain M3750 (MATa ura3-52) [28] was
used as the reference strain in all experiments unless otherwise
indicated, while the barcode-tagged deletion-mutant library was
from Johnston and coworkers [29]. S1278b (10560-2B; MATa
ura3-52 leu2:hisG his3:hisG) was used for biofilm susceptibility
experiments [30]. Complex YPD medium [31] was used in all
experiments except for amino acid release and biofilm where cells
were grown in synthetic complete medium [31]. LTX109 (Lytixar;
LytixBiopharmaAS, Oslo, Norway) and amphotericin B (Sigma)
were dissolved in water and stock solutions were kept at 220uC.
Broth microdilution minimal inhibitory concentrations
Minimal inhibitory concentration (MIC) values were measured
under static conditions in polystyrene microtiter plates. Two-fold
dilution series of antifungal drug were prepared in fresh YPD
medium and distributed to microtiter-plate wells. Overnight
cultures of wild type (WT) S288c were diluted and added to
antifungal-containing wells to a final concentration of 26105 cells/
ml. Growth inhibition was recorded with absorbance at 600 nm
after 24 hours at 30uC. The lowest drug concentration resulting in
90% growth inhibition was the MIC. MIC values of LTX109 were
determined three times with triplicate measurements, while MIC
values of amphotericin B was determined once with triplicate
measurements.
Killing kinetics
Overnight cultures of S. cerevisiae were diluted in fresh, preheated
YPD to 46105 cells/ml and incubated at 30uC with aeration.
Exponential growth phase cells were challenged with LTX109 or
amphotericin B at concentrations that were five times the MIC.
Control samples were treated with water to ensure that cells
applied in the time-kill experiment were in exponential growth
phase. Samples were taken at the indicated time points, diluted 10-
fold, and plated on YPD agar to determine colony forming units
(CFUs). The time-kill experiment was conducted in triplicates.
Acidification assay
Glucose-induced acidification was measured as previously
described [32] with modifications. Exponentially growing S.
cerevisiae cells were washed and resuspended in sterile water to a
final concentration of 108 cells/ml. Cells were subsequently
incubated with LTX109 (100 mg/ml) or water (control) for 10
minutes before the assay was initiated by addition of glucose to a
final concentration of 2% (w/v). The assay was conducted in
triplicate at room temperature with continuous magnetic stirring.
The assay was stopped by sampling at indicated time points,
followed by immediate centrifugation (20006g for two minutes).
pH of the resulting supernatants was measured and changes in
extracellular H+ concentration were calculated by applying the
obtained values to the equation pH=2log [H+].
Potassium release
Exponentially growing S. cerevisiae were harvested and resus-
pended in sterile water as described above. The potassium release
assay was initiated by addition of LTX109 to a final concentration
of 10 times the MIC. Samples treated with water instead of
LTX109 served as control. The assay was stopped by centrifuga-
tion of samples (13,0006g for 1 min) at indicated time points.
Supernatants were transferred to sterile microtubes for spectro-
metric analysis. Potassium concentrations were measured with a
FLM3 flame photometer (Radiometer). A standard concentration
curve was generated from diluted S3336 urine flame standard
(Radiometer). For spectrometric analysis, 5 ml of sample was
added to 1000 ml of S3336 lithium solution (Radiometer).
Experiments were carried out in triplicates at room temperature.
SYTOX Green uptake
SYTOX Green uptake was measured as previously described
[33] with modifications. Exponentially growing S. cerevisiae cells
were centrifuged, washed and suspended in 5 mM SYTOX Green
(Life Technologies) to a final concentration of 108 cells/ml.
LTX109 or water (control) was added to cell suspensions and
SYTOX Green uptake was recorded microscopically after 4, 8,
16, 32, 64 and 128 minutes. Fluorescence was recorded with a
Nikon Eclipse (Tokyo, Japan) fluorescence microscope equipped
with a F36–525 EGFP HC-filter set (AHF Analysentechnik).
Experiments were carried out at room temperature. SYTOX
green uptake upon LTX109 treatment was observed in three
independent experiments.
Amino acid release
Exponentially growing S. cerevisiae were harvested and suspend-
ed in sterile water or water with 10 times the MIC of LTX109 to a
final concentration of 26106 cells/ml. Loss of free amino acids
from cells was recorded at room temperature after 16 minutes
LTX109 exposure by instant centrifugation and subsequent
HPLC of the cell free supernatant. Amino acids were detected
and quantified by reverse-phase HPLC using an LKB-Alpha Plus
amino-acid analyzer and a mixture of L-a-amino acids, 1 nmol
each, as standards. The experiment was repeated three times.
Identification of LTX109-resistant mutants
Haploid knockout mutants of approximately 4000 nonessential
genes in the S288c deletion mutant library [29] were pooled.
About 106 cells from the mutant pool were transferred to YPD
agar containing 10 times the MIC of LTX109. After 72 hours at
30uC, 17 colonies were picked from the LTX109 plates. LTX109-
resistant clones were identified by PCR amplification and Sanger
sequencing of the unique barcode tag of each mutant. PCR
templates were DNA from clonal isolates of LTX109-resistant
mutants. Primers were 59-GATGTCCACGAGGTCTCT and 59-
CTGCAGCGAGGAGCCGTAAT. Gene deletions were identi-
fied using barcode sequences in the Stanford SGD deletion
database.
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Spot test
Exponentially growing S. cerevisiae cells were diluted to 107 cells/
ml and 6 ml of a 10-fold dilution series was spotted on YPD agar
and YPD agar containing 10 times the LTX109 MIC. Plates were
incubated for 24 hours at 30uC and growth results were recorded.
Biofilm susceptibility
S. cerevisiae (S1278b) cells were grown in Lab-TekTM Chamber
SlideTM System; PermanoxH (NUNC, Denmark) [34,35] in 1 ml
synthetic complete medium. Cells were initially allowed to form
biofilm for 12 hours before LTX109 was added for 5 hour in a
concentration of 0 or 70 mg/ml. The biofilm was subsequently
stained 15 minutes with Syto 9 (Invitrogen, Irvine, CA) for life cell
staining and propidium iodine for dead cell staining before
confocal laser scanning microscopy (CLSM). Imaging was carried
out using a 63x/0.95NA water immersion lens. CLSM was
performed with a Zeiss LSM510 microscope. Staining of biofilm
treated with LTX109 was repeated in four independent experi-
ments.
Results
Fungicidal properties of LTX109
We tested the antifungal properties of the peptidomimetic
LTX109 on the yeast S. cerevisiae using microdilution. LTX109 had
antifungal activity against S. cerevisiae at 26105 cells/ml with a
MIC value of 8 mg/ml compared to 2 mg/ml amphotericin B.
Assay to determine the killing kinetics of LTX109 against S.
cerevisiae revealed rapid and efficient fungicidal properties resulting
in a 3-log reduction in viable cells within one hour, while
amphotericin B required 90 minutes to achieve a similar fungicidal
effect when using drug concentrations in multiples of MIC (Fig. 1).
Additionally, LTX109 reduced the yeast population to the
detection limit within only 2 hours, an effect that was not achieved
by amphotericin B in the first 3 hours of exposure.
Exposure to LTX109 disrupts plasma membrane integrity
The speed with which LTX109 killed S. cerevisiae suggested that
the compound was acting directly on the plasma membrane. To
investigate the effect of LTX109 on plasma membrane integrity,
we measured H+ efflux, ion loss, loss of amino acids and uptake of
the fluorophore SYTOX Green across the plasma membrane.
Yeast cells treated with glucose acidify their surroundings
primarily by active transport of H+ by the plasma membrane H+-
ATPase [36]. We found that glucose-induced acidification was
completely absent when cells were treated with LTX109 for 10
minutes before glucose addition (Fig. 2A). These results suggested
that LTX109 decoupled the plasma membrane potential directly
or indirectly by inhibition of e.g. ATP synthesis.
We next tested the loss of potassium from cells treated with
LTX109. Potassium release occurred immediately and increased
during the first 16 minutes of exposure to LTX109, reaching a
steady state that was more than four times higher than the
maximum of the untreated control (Fig. 2B). Much of the K+ that
was lost was detected within the first two minutes of challenge with
a high LTX109 concentration. These results suggested that
LTX109 acted by direct interaction with and disturbance of the
plasma membrane rather than through indirect inhibition of
metabolism or another intracellular pathway.
To investigate if LTX109 treatment also led to loss of other
small molecules, cells were treated with LTX109 for 16 minutes
and free amino acids measured in the extract. Yeast cells treated
with LTX109 lost substantial amounts of at least 14 different
amino acids whereas cells treated with water only leaked aspartate
(Fig. 3). The loss corresponds well to the pool of intracellular
amino acids found in other experiments [37], suggesting that most
if not all free amino acids are depleted from cells treated with
LTX109.
We finally investigated if the membrane potential decoupling
was a consequence of plasma membrane destabilization by
monitoring the uptake of the 600-Dalton nucleic acid stain
SYTOX Green. SYTOX is an inorganic compound that
fluoresces upon DNA binding and SYTOX Green can only enter
a cell and fluoresce if the plasma membrane is compromised [38].
We found that untreated cells were impermeable to SYTOX
Green, while cells treated with LTX109 became permeable. The
dye was visible in the nucleus of LTX109-treated cells after only
eight minutes (Fig. 2C) and fluorescence increased with LTX109
exposure time.
Defects in sphingolipid synthesis lead to LTX109
resistance
To gain further insight into the LTX109 mode of action, we
screened a collection of haploid S. cerevisiae knockout mutants for
LTX109 resistance. We isolated 17 mutants that were resistant to
LTX109 at 10 times the MIC on YPD agar. Eight genes conferred
LTX109 resistance when deleted (Table 1; Fig. 4A). Six of the
identified genes (SUR1, FEN1, SUR2, IPT1, SKN1, ORM2) were
involved in the biosynthesis of sphingolipids, which are a major
plasma membrane component. Fen1p and Sur2p are involved in
synthesis of ceramides, which are precursors for inositol phospho-
ceramide (IPC), the first complex sphingolipid in the synthesis
pathway [39] (Fig 4B). Fen1p elongates long-chain fatty acids that
are linked to a sphingoid base to form ceramides [40] and Sur2p
hydroxylates dihydrosphingosine (DHS) to form phytosphingosine
(PHS) [41], which is the most abundant sphingoid base in yeast
ceramides [39]. Sur1p mannosylates IPC to form the intermediate
sphingolipid mannose inositol phosphoceramide (MIPC) [42] and
Skn1p and Ipt1p have similar functions in the biosynthesis of the
terminal sphingolipid mannosyl di-inositol phosphorylceramide
(M(IP)2C) [43]. Orm2p is a regulator of the sphingolipid
biosynthesis that links the biosynthesis to the regulatory Target
Of Rapamycin pathway [44]. Mutants that fail to activate Orm2p
have reduced levels of sphingolipids as do fen1, sur1, ipt1 and skn1
Figure 1. Fungicidal properties of LTX109 and amphotericin B.
Time-kill kinetics of exponentially growing yeast cells exposed to water
(circles) or five times the MIC of LTX109 (40 mg/ml) (squares) or
amphotericin B (10 mg/ml) (triangles). Viability was examined every half
hour as CFUs. Each data point is the average of three individual
measurements 6 standard deviation.
doi:10.1371/journal.pone.0069483.g001
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mutants [40,43,45,46], suggesting a role of sphinolipids in
sensitivity to LTX109.
One LTX109-resistant mutant was affected in the YSP2 gene,
which is involved in apoptosis, and another was affected in OPI9.
OPI9 has an unknown function but partly overlaps with VRP1,
which encodes an actin-associated protein with a role in actin
filament organization. The opi9 mutant therefore also has a partial
deletion of VRP1, so the LTX109-resistance phenotype could be
caused by loss of Vrp1p activity. Resistance of each mutant was
confirmed by spot-testing diluted yeast suspensions on YPD agar
containing LTX109 (Fig. 4A). Five of the mutants affected in
sphingolipid biosynthesis showed similar, high resistance towards
LTX109 (sur1, fen1, sur2, ipt1 and skn1).
LTX109 efficiently kill S. cerevisiae growing as biofilm
Because S288c is incompetent of biofilm growth [47,48] we
used the S1278b strain background to test the antifungal activity of
LTX109 against S. cerevisiae biofilm. To visualize the antifungal
properties of LTX109, we used CLSM in combination with Syto 9
DNA viability stain and propidium iodide that only penetrates
damaged cell membranes. Intermediate (12 h) S. cerevisiae biofilm
grown in batch culture slides were treated with 10 times MIC
LTX109 for 5 hours before LIVE/DEAD staining and CLSM
(Fig. 5). The LTX109 treatment killed the majority of the biofilm
population as indicated by uptake and staining of dead cells with
propidium iodide (Fig. 5), suggesting that LTX109 is also an
efficient anti-biofilm agent in addition to its fungicidal activity
against planktonic cells in exponential growth phase.
Discussion
This study demonstrated the fungicidal activity of the
peptidomimetic LTX109. Antimicrobial peptidomimetics are
peptide-like compounds, of which most are bactericides [49–53].
Figure 2. Transport of H+, K+ and a fluorescent dye by cells treated with LTX109. (A) Glucose-induced acidification of medium by yeast
cells. Exponentially growing S. cerevisiae was washed and suspended in sterile water and exposed to 100 mg/ml LTX109 (squares) or water (circles)
before glucose addition at time zero. Medium pH was measured and H+ concentration calculated from pH=2log [H+]. Each data point is the average
of three individual measurements with standard deviations as error bars. (B) Potassium release from yeast cells. Exponentially growing yeast cells
were washed, resuspended in water, and challenged with 100 mg/ml LTX109 (squares) or water (circles) at time zero. Potassium release was measured
using flame atomic absorption spectrometry in binary increasing intervals. Each data point is the average of three individual measurements 6
standard deviation. (C) Nomarski (left) and fluorescent (right) microscopy of SYTOX Green-stained yeast cells. Exponential growing cells were exposed
to 100 mg/ml LTX109 and SYTOX Green uptake was monitored. Cells treated with SYTOX Green and 0 mg/ml LTX109 served as control. SYTOX green
uptake upon LTX109 treatment was observed in three independent experiments.
doi:10.1371/journal.pone.0069483.g002
Figure 3. Efflux of amino acids from cells treated with LTX109.
Exponentially growing yeast cells were washed, resuspended in water,
and challenged with 70 mg/ml LTX109 (black bars) or water (grey bars)
for 16 minutes. Amino acids (one letter code) in the extracellular
medium were subsequently measured by HPLC. Each data point is the
average of three individual measurements 6 standard deviation.
doi:10.1371/journal.pone.0069483.g003
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LTX109 was previously shown to have bactericidal activity [27].
The arginine–tertbutyl tryptophan–arginine sequence of LTX109
makes it amphipathic, with two bulky side groups and two cationic
side groups that are proposed to interact with negatively charged
bacterial cell membranes [26].
We found similar killing kinetic for LTX109 and the membrane
permeabilizing drug amphotericin B, suggesting that the two
compounds could have a related mode of action. The rapid uptake
of the fluorescent dye SYTOX Green, potassium and amino acid
efflux from cells exposed to a high concentration of LTX109
suggest that this drug disturbs the plasma membrane by direct
interaction with one or several components in the plasma
membrane. Furthermore, inability of LTX109 treated cells to
acidify their surrounding media support an effect on the cell
membrane.
These results are similar to results with amphotericin B, which
also causes yeast cells to inhibit glucose-induced acidification [32]
and to release potassium as a consequence of general membrane
disorganization [54,55].
The high concentration of drug could have obscured other toxic
effects of LTX109 on S. cerevisiae, so we cannot exclude that
LTX109 has other effects in addition to membrane disruption as
previously discussed for peptide drugs [56].
To gain further insight into the mode of function of LTX109,
we screened for resistant mutants. Six of eight resistance mutants
were affected in sphingolipid biosynthesis, and five of these showed
similar, high resistance towards LTX109 (Fig. 4). fen1, sur1, ipt1
and skn1 mutants all have reduced amount of sphingolipids
[40,43,45,46] as do mutants that reduce Orm2p activity [44],
suggesting an essential role of complex sphingolipids in sensitivity
to LTX109. Lack of Sur2p lead to decreased sphinganine
hydroxylation, but does not prevent formation of MIPC [57].
Furthermore, the fen1 mutant produce reduced amount of
sphingolipids containing the C26 acyl group [40]. The resistance
phenotype of the sur2 and fen1 mutants therefore suggested that it
is not only the quantity, but also the structural modifications that
occur during sphingolipid synthesis that is required for optimal
LTX109 activity. The terminal steps of sphingolipid biosynthesis
in yeasts are MIPC and M(IP)2C. The fact that these lipids are
reduced in the resistant mutants suggests that MIPC and M(IP)2C
are essential for the fungicidal activity of LTX109, either by direct
interaction with LTX109 or by interaction with another mem-
Figure 4. Mutants in sphingolipid biosynthesis are resistant to
LTX109. (A) Spot test of wild type (WT) S. cerevisiae and eight deletion
mutants identified by screening a deletion collection for LTX109
resistance. Exponentially growing yeast was resuspended in YPD to 107
cells/ml and serially diluted 1:10. Aliquots (6 ml) were spotted on solid
YPD plates containing 70 mg/ml LTX109 (left panel), and without
LTX109 (right panel). (B) S. cerevisiae sphingolipid biosynthetic pathway.
doi:10.1371/journal.pone.0069483.g004
Table 1. S. cerevisiae genes that confer LTX109 resistance upon deletion.
Deleted gene and function ORF Gene product n
Sphingolipid biosynthesis
SUR1 YPL057C Mannosylinositol phosphorylceramide (MIPC) synthase catalytic subunit 2
SUR2 YDR297W Sphinganine C4-hydroxylase 8
ORM2 YLR350W Sphingolipid homeostasis. Interacts with serine palmitoyl transferase (SPT) 1
IPT1 YDR072C Inositolphosphotransferase, involved in synthesis of mannose-(inositol-P)2-ceramide (M(IP)2C) 1
FEN1 YCR034W Involved in membrane-bound fatty acid elongation up to 24 C (ceramide precursor) 1
SKN1 YGR143W Involved in the terminal M(IP)C RM(IP)2C process 2
Apoptosis
YSP2 YDR326C Mitochondrial protein in programmed cell death. 1
Unknown function
OPI9 YLR338W Dubious ORF unlikely to encode a protein. Partly overlaps VRP1 1
n, number of mutants identified.
doi:10.1371/journal.pone.0069483.t001
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brane components that is the target for LTX109. It does however
seem less likely that a component other than sphingolipids is the
target for LTX109 for two reasons, (i) mutants depleted of the
target would be expected to appear in the screen for mutants
resistant to LTX109. (ii) Alternatively, the target could depend on
sphingolipids for optimal activity, be essential for growth and thus
not appear in the screen, but then fen1, sur1, ipt1, skn1 and orm2
mutants would be expected to have reduced growth rates which
they do not (Fig. 4).
Sphingolipids are located primarily in the plasma membrane
[58] and are often clustered together with ergosterol in lipid rafts
[59]. Sphingolipids are not only a structural component of the cell
membrane, but serve vital functions in the heat-shock response,
cell cycle arrest, signaling pathways, endocytosis and protein
trafficking [60,61]. Fungal sphingolipids are highly similar to each
other [62,63], and the biosynthesis of complex fungal sphingolipids
is distinctly different from mammals [64]. This makes the fungal
sphingolipids attractive antifungal drug targets and several natural
compounds with anti-IPC synthase activity have been identified
[65–67].
The terminal M(IP)2C is the major sphingolipid in the fungal
plasma membrane [46] and has previously been suggested as a
target for the plant defensin Dahlia merckii antimicrobial peptide 1
(DmAMP1) [43,68,69]. DmAMP1 is a 50 amino acid amtimicro-
bial peptide that leads to nonselective passage of potassium,
calcium [70] and SYTOX Green [33]. Hence, DmAMP1 and
LTX109 could have similar modes of action, although DmAMP1
does not contain the Arg-Trp-Arg sequence that serves as basis for
LTX109.
Amphotericin B is currently the last in line treatment option for
severe fungal infections [71]. Alternative drug candidates might
therefore be developed for treatment in cases where use of
amphotericin B becomes limited due to resistance. Biofilm
formation on medical devices is a major nosocomial problem
and causes multidrug resistance [13]. Only a few of the current
systemic antifungals have activity against yeast biofilms [72,73],
but often it requires removal of the implant for effective treatment
[74]. Peptide antibiotics including LTX109 analogues have been
shown to be efficient drugs to kill bacterial biofilm cells [25,50].
This study shows for the first time a peptidomimetic with activity
against yeast biofilm. This observation suggests antifungal
peptidomimetics with rapid killing kinetics and membrane
permeabilizing activities are attractive drugs for yeast biofilm
treatment.
In conclusion, we have shown the efficient fungicidal properties
of a synthetic peptidomimetic, LTX109, that killed the yeast S.
cerevisiae with fast killing kinetics and complete eradication of viable
cells in exponential growth phase. We found that yeast cells treated
with a high concentration of LTX109 became permeable to free
amino acids, potassium and SYTOX Green and prevented proton
extrusion in response to a pulse of glucose. Fungal susceptibility to
LTX109 depended on biosynthesis of sphingolipids. The sphin-
golipids M(IP)2C and its precursor MIPC are found in fungal, but
not human membranes, making LTX109 and derivatives attrac-
tive drug candidates for fungal infection treatment as alternatives
to amphotericin B.
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